SiRNA技术沉默Stat3对膀胱肿瘤的生长抑制作用
|
摘要
目的:研究Stat3基因沉默在膀胱癌细胞增殖凋亡中的作用并探讨其相关机制。
方法:(1)应用免疫组织化学染色方法检测膀胱移行细胞癌标本中Stat3蛋白表达情况。(2)以Stat3己知序列为靶点,构建能够稳定表达Stat3 siRNA的重组质粒。(3)应用真核细胞转染技术转染膀胱癌细胞株T24,观察Stat3的表达及对细胞凋亡的影响。(4)复制裸鼠膀胱癌皮下移植瘤模型及膀胱癌原位移植瘤模型,应用沙门氏菌运载特异性siRNA-Stat3表达载体对膀胱肿瘤作用观察。
结果:(1)Star3的表达随膀胱肿瘤病理分级的等级的升高而增加。(2)成功构建pSilencer~(TM)neo 3.1-H1-Stat3 siRNA表达质粒。(3)体外实验证明该质粒对膀胱癌细胞具有增殖抑制及促进凋亡的作用。(4)体内实验证明Si-Stat3具有明显抑制肿瘤的生长作用。(5)减毒沙门氏菌可以运载质粒到达深部肿瘤并可起到抑制肿瘤生长的作用。
结论:采用Stat3特异性siRNA基因表达系统对膀胱癌的治疗取得了显著效果;并首次以减毒鼠伤寒沙门氏菌为siRNA-Stat3运载体进行膀胱肿瘤的有效靶向治疗。
本研究所采用的技术路线及实验结果在国内外均未见报道。
Bladder cancer is one of the most common urological malignant diseases in the world. Bladder cancer was the fourth in men and the eighth in women most common cancer respectively. In 2006, in Europe, an estimated 104,400 incident cases of bladder cancer were diagnosed, of which 82,800 were diagnosed in men and 21,600 in women. This represents 6.6% of the total cancers in men and 2.1% in women, with an estimated male-to-female ratio of 3.8:1. Bladder cancer resulted in 4.1% of total deaths for cancer in men and 1.8% of total deaths in women. At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive disease and 30% as muscle-invasive disease. The most important performances of urothelial cancers of the bladder are metachronous or synchronous multifocal occurrence with high recurrence .Operation especially radical cystectomy is the standard treatment for muscle invasive bladder cancer in most countries in the world. However when patients , with an initially non-insive and invasive bladder cancer, presenting with pT0 or T1 status at first resection are selected for transurethral resection of bladder tumour(TURBT)alone, about 60-99% of them will recurs and 15-20% of them progressed during organ-preserving treatment. Organ-preserving treatment such as transurethral resection of bladder tumour, followed by neoadjuvant chemotherapy, radiotherapy and immune revulsive, was identified as a prognostically important variable. However these therapeutic means we use can't stop the progression and recurrence of bladder cancer and at the same time the side effects of chemotherapy, radiotherapy and drugs fast in patients remain the tough bladder-preserving strategy, the bladder remains a potential source of recurrence. Therefore many scholars is still exploring new effective treatments of bladder cancer. Gene therapy was identified as that functional genes are transfected into the patients'body to correct the defective gene or block the overexpressed gene for treatment and prevention strategies of disease. For more than twenty years research gene therapy has gradually become mature and is accepting as extremely promising approach to treating cancer after regular treatment such as operation, chemotherapy and radiotherapy. Human being pay close attention to targeted therapy today. Inhibing the expression of activated oncogene in cancer cells has gradually been one trend of gene therapy.The discovery that RNAi works in mammalian cell function, its use as a tool to understand or screen for genes functioning in cellular pathways in normal and diseased cells and animals, and its potential for therapeutic gene silencing.
Signal transducers and activators of transcription( Stat)proteins comprise a family of transcription factors latent in cytoplasm that consists of seven different members. They were discovered in the course of studies of signaling specificity from IFN receptors.
The Stat transcription factors family are activated by a series of extracellular signaling proteins such as cytokine, growth factors, and Hormones that bind to specific cell-surfacer eceptors. The resulting signal transduction pathways permit them to play different roles in normal physiological cell processes, such as differentiation, proliferation, apoptosis and angiogenesis. However, aberrant activation of Stat Signaling gives rise to different pathological events, for example, cell transformation and oncogenesis. In addition, constitutively activated Stat3 induces cellular transformation in vitro and tumor formation in nude mice.Thus, Stat3 may be an important molecular target for tumor therapy. Stat3, a member of the Stat family, is a key signal transduction protein that mediates signaling by numerous cytokines, peptide growth factors, and oncoproteins. Accumulating evidence demonstrates that Stat3 activation plays important roles in cell diferentiation, proliferation, development and apoptosis. Elevated activity of Stat3 has been detected frequently in a lot of human tumors, including carcinoma of rectum, hematologic malignancies, head and neck, breast and prostate cancer. Cell strains from multiple myelomas that have become growth factor independent require constitutively active Stat3 to protect against apoptosis. In addition, constitutively activated Stat3 induces cellular transformation in vitro. Stat3 participates in oncogenesis through up-regulation of genes encoding apoptosis inhibitors (Bcl-xL, Mcl-1 and survivin), cell-cycle regulators (cyclin D1 and c-Myc) and inducers of angiogenesis vascular endothelial growth factor (VEGF).
Stat3 is activated by phosphorylation at tyrosine residue 705 (Y705), which leads to dimer formation, its nuclear translocation, DNA binding and target gene transcription. Phosphorylation of Stat3 at tyrosine 705 (Y705) is critically its dimerization and nuclear translocation; both prerequisites of Stat3 activation. Thus, we considered that inhibiting this phosphorylation at residue 705 might reduce VEGF expression in tumor cells.
Thus, the Stat3 signaling pathway may represent a potential molecular target for novel therapeutic approaches for bladder cancer. As outlined below, Stat3 can be targeted at one or more steps. Strategies to target Stat3 include decreasing Stat3 levels, reducing tyrosine phosphorylation of Stat3 and receptor complexes, reducing Stat3 recruitment to receptor complexes and its dimerization, and reducing Stat3 binding to promoters. Studies have shown that using a variety of approaches, such as tyrosine kinase inhibitors such as tyrphostin AG490, Antisense oligonucleotides, decoy oligonucleotides, and dominant-nagative Stat3 proteins can inhibit Stat3 expression in cancer cells to surpress proliferation and induce apoptosis.
Small interfering RNA (siRNAs)are short doubles tranded RNA (dsRNA)Molecules that can target complementary mRNAs for degradation via a Cellular process termed RNA interference (RNAi). RNAi is usually activated by introducing long double-stranded RNA molecules into cells which are cleaved into 21-nt to 23-nt RNAs referred to as siRNAs by an endonuclease named Dicer in animal cells. The siRNA molecules then serve as a guide for sequence-specific degradation of homologous mRNAs. siRNA has been used for functional analysis of genes in many species including invertebrates, plants, and mammalian cells. Recently, siRNA has emerged as powerful RNAi reagents for gene silencing and inhibition of viral propagation. The potential of using siRNA for silencing specific genes has been demonstrated in treatment of viral diseases and cancer.
At present, the primary limitation of cancer therapy is lack of selectivity of therapeutic agents for tumor cells. Current efforts are focused on discovering and developing anticancer agents that selectively target only tumor cells and spare normal tissue to improve the therapeutic index. It has been known that attenuated Salmonella typhimurium accumulate and replicate preferentially in tumors to a level that is 1,000-fold greater than found in cells from normal tissues. S. typhimurium is a facultative anaerobic bacterium, which is capable of replicating preferentially in tumor cells and inhibition of growth, is associated with lysis of tumors with a necrotic/hypoxic centre. These observations suggest that the tumor targeting bacteria in combination with other antitumor agents, represents a promising strategy for the treatment of primary and metastatic tumors.
The present study was designed to investigate the potentiall use of siRNA to block Stat3 expression, its efect on growth and apoptosis of human bladder cancer cells, and effect on tumor formation in Balb/c nude mice.We construct pSHlSi-Stat3 and transfected it in bladder cancer cells to observe its inhibition effect on Stat3 expression and its effect on growth, proliferation and apoptosis of bladder cancer cells T24. We further use attenuated S. typhimurium carrying Si-Stat3 to observe its therapeutic effect on nude mice transplantation tumor. Our results showed that targeting Stat3 signaling using siRNA technique may serve as a novel therapeutic Strategy for treatment of bladder cancer.
However, to our knowledge, no reports have been published to date concerning the effect of siRNA against the Stat3 gene in bladder cancers cells. In our studies we have used T24 bladder cancer cells, which have shown to be of value for the study of bladder cancer.
Study objectives:
(1) to determine if Stat3 siRNA can inhibit the expression of Stat3 gene in bladder cancer cells in vivo and in vitro.
(2) to explore that the attenuated S. typhimurium with siRNA-Stat3 plasmids were induced to primary tumor and subcutaneous transplantation tumor model for developing more effective treatment for bladder cancer.
Methods:
(1) Study on the Expression of Stat3, Survivin, VEGF in tissue of Bladder Transitional cell carcinoma and their Clinical Significances
(2) Construction of a recombinant plasmid expressing Stat3 siRNA
Using Stat3 gene sequences from GenBank, selected suitable target site,synthesized oligonucleotides as DNA template encoding Stat3 siRNA, annealed and ligated into pSilencer~(TM) neo3.1-H1 expression vector to construct plasmid pSilencer~(TM) neo3.1-H1-Stat3(pH1Si-Stat3, Si-Stat3).
(3) Studies in vitro:
The bladder cancer cell lines were transfected with plasmids pH1Si-Stat3. To determine the expression of the Stat3 at 72h after transfection, semi -quantitative RT-PCR analysis , Western blot and immunocytochemical detection analyses with the samples extracted from transfected and control cells were performed. The cells were also analyzed for cell cycle phase distribution and apoptosis rate by flow cytometry, and stained by acridine orange to detect the early apoptosis.MTT assay showed that the growth-inhibition rate of the Stat3 siRNA groups was significantly higher than that of the vehicle group or plasmid group.
(4) Studies in vivo:
To study the effects of pHlSi-Stat3 on bladder tumor growth in vivo, we developed a nude mouse tumor xenograft model.First of all, mice were transplanted via.s.c. with T24 cells into the left hip for tumor-bearing nude mice.Then the primary tumor and spontaneous metastasis mice models were established by surgical orthotopic implantation in nude mice. On day 14 and 21, palpable tumors had developed in the spontaneous metastasis mice models, and Attenuated S. typhimurmm carried Si-Stat3 or scramble plasmids were introduced via intratumor injection into the mice. On day 10 and 17, the primary metastasis bladder tumors had developed in the primary bladder cancer metastasis models of nude mice, and Attenuated S. typhimurmm carried Si-Stat3 or scramble plasmids were introduced via intraperitoneal injection into the mice.The HE staning was used to detect the level of the tumor tissues.The TUNEL assay was used to detect the apoptosis of tumor cells. RT-PCR and Western blot analysis were used to detect the expression levels of related genes and proteins. Immunohistochemistries for Stat3, VEGF, Survivin, Bcl-2 and Ki-67 were performed to determine the distribution of their related proteins.
Results:
(1) Stat3, Survivin,VEGF protein showed positive expression of 64%, 56% and 68% respectively in bladder cancer tissue than in normal bladder mucosa with statistical significience(p<0.01).The expression rate of Stat3, Survivin,VEGF were strongly correlated whit pathological grade and clinical statge of the TCC (P<0.01) . And these three factors were showed hightly negative correlation with prognosis of these patients(with p<0.01;p<0.01; p<0.05, respectively) .
(2) The plasmids pHlSi-Stat3 containing siRNA-Stat3 were constructed, and confirmed by restriction enzyme digest and sequence analysis.
(3) Transfection with pHlSi-Stat3 inhibited the growth of T24 cells and induced apoptosis effect for suppression of tumors. The results from semi-quantitative RT-PCR analysis, immunocytochemical detection and Western blot analyses for the samples from T24 cells after transfection with Si-Stat3, demonstrated that the plasmids containing Si-Stat3, could specifically reduce Stat3 expression. The Si-Stat3 transfected groups showed: (i) that the total Stat3 expression levels were not reduced, (ii) that the expression levels of Bcl-2, cyclin D1, survivin and VEGF were significantly depressed. The results of MTT, FCM and acridine orange detection assay demonstrated that the Si-Stat3 group showed remarkable apoptosis effects compared to untreated and scramble groups. Examination of subcutaneous tumors in nude mice showed that in the group transfected with Si-Stat3, both the average weights and volumes of the tumors were lower than those of other groups. The results indicated the effect for suppression of tumor growth by the siRNA-Stat3.
(4) Systemic administration of attenuated S. typhimurium carrying Si- Stat3 for bladder cancer therapy.
An animal model of bladder cancer demonstrating primary bladder tumor and subcutaneous metastasis by surgical orthotopic implantation in nude mice has been obtained. In primary bladder tumor model and subcutaneous metastasis bladder tumor model ,the group treated with attenuated S. typhimurium carrying Si-Stat3 and Si-scramble plasmids introduced via. intratumor injection or via intraperitoneal injection showed selectively growth suppression of tumors compared with untreated and Si-Scramble groups, respectively. Average tumor weights and volumes in the mice treated with Si-Stat3 carried by Salmonella were significantly lower than the untreated and scramble groups. Average tumor weights and volumes in the scramble groups notable showed lower than that of the untreated. The tumor tissue cells developed apoptosis.
Conclusions:
(1) we successfully constructed pH1Si-Stat3 plasmid.
(2) In this studies, we show for the first time that a bladder cancer therapy with SiRNA-Stat3 showed a remarkable effect with respect to suppression of tumors in vitro and in a nude mice model, and Si-Stat3 which was carried by attenuated S. typhimurium showed significant suppression effect for primary transplanted tumor growth of bladder cancer. RNAi technique may be a promising tool for cancer therapy.
(3) Stat3 signaling pathway is an ideal molecule target to gene therapy of bladder cancer.
方法:(1)应用免疫组织化学染色方法检测膀胱移行细胞癌标本中Stat3蛋白表达情况。(2)以Stat3己知序列为靶点,构建能够稳定表达Stat3 siRNA的重组质粒。(3)应用真核细胞转染技术转染膀胱癌细胞株T24,观察Stat3的表达及对细胞凋亡的影响。(4)复制裸鼠膀胱癌皮下移植瘤模型及膀胱癌原位移植瘤模型,应用沙门氏菌运载特异性siRNA-Stat3表达载体对膀胱肿瘤作用观察。
结果:(1)Star3的表达随膀胱肿瘤病理分级的等级的升高而增加。(2)成功构建pSilencer~(TM)neo 3.1-H1-Stat3 siRNA表达质粒。(3)体外实验证明该质粒对膀胱癌细胞具有增殖抑制及促进凋亡的作用。(4)体内实验证明Si-Stat3具有明显抑制肿瘤的生长作用。(5)减毒沙门氏菌可以运载质粒到达深部肿瘤并可起到抑制肿瘤生长的作用。
结论:采用Stat3特异性siRNA基因表达系统对膀胱癌的治疗取得了显著效果;并首次以减毒鼠伤寒沙门氏菌为siRNA-Stat3运载体进行膀胱肿瘤的有效靶向治疗。
本研究所采用的技术路线及实验结果在国内外均未见报道。
Bladder cancer is one of the most common urological malignant diseases in the world. Bladder cancer was the fourth in men and the eighth in women most common cancer respectively. In 2006, in Europe, an estimated 104,400 incident cases of bladder cancer were diagnosed, of which 82,800 were diagnosed in men and 21,600 in women. This represents 6.6% of the total cancers in men and 2.1% in women, with an estimated male-to-female ratio of 3.8:1. Bladder cancer resulted in 4.1% of total deaths for cancer in men and 1.8% of total deaths in women. At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive disease and 30% as muscle-invasive disease. The most important performances of urothelial cancers of the bladder are metachronous or synchronous multifocal occurrence with high recurrence .Operation especially radical cystectomy is the standard treatment for muscle invasive bladder cancer in most countries in the world. However when patients , with an initially non-insive and invasive bladder cancer, presenting with pT0 or T1 status at first resection are selected for transurethral resection of bladder tumour(TURBT)alone, about 60-99% of them will recurs and 15-20% of them progressed during organ-preserving treatment. Organ-preserving treatment such as transurethral resection of bladder tumour, followed by neoadjuvant chemotherapy, radiotherapy and immune revulsive, was identified as a prognostically important variable. However these therapeutic means we use can't stop the progression and recurrence of bladder cancer and at the same time the side effects of chemotherapy, radiotherapy and drugs fast in patients remain the tough bladder-preserving strategy, the bladder remains a potential source of recurrence. Therefore many scholars is still exploring new effective treatments of bladder cancer. Gene therapy was identified as that functional genes are transfected into the patients'body to correct the defective gene or block the overexpressed gene for treatment and prevention strategies of disease. For more than twenty years research gene therapy has gradually become mature and is accepting as extremely promising approach to treating cancer after regular treatment such as operation, chemotherapy and radiotherapy. Human being pay close attention to targeted therapy today. Inhibing the expression of activated oncogene in cancer cells has gradually been one trend of gene therapy.The discovery that RNAi works in mammalian cell function, its use as a tool to understand or screen for genes functioning in cellular pathways in normal and diseased cells and animals, and its potential for therapeutic gene silencing.
Signal transducers and activators of transcription( Stat)proteins comprise a family of transcription factors latent in cytoplasm that consists of seven different members. They were discovered in the course of studies of signaling specificity from IFN receptors.
The Stat transcription factors family are activated by a series of extracellular signaling proteins such as cytokine, growth factors, and Hormones that bind to specific cell-surfacer eceptors. The resulting signal transduction pathways permit them to play different roles in normal physiological cell processes, such as differentiation, proliferation, apoptosis and angiogenesis. However, aberrant activation of Stat Signaling gives rise to different pathological events, for example, cell transformation and oncogenesis. In addition, constitutively activated Stat3 induces cellular transformation in vitro and tumor formation in nude mice.Thus, Stat3 may be an important molecular target for tumor therapy. Stat3, a member of the Stat family, is a key signal transduction protein that mediates signaling by numerous cytokines, peptide growth factors, and oncoproteins. Accumulating evidence demonstrates that Stat3 activation plays important roles in cell diferentiation, proliferation, development and apoptosis. Elevated activity of Stat3 has been detected frequently in a lot of human tumors, including carcinoma of rectum, hematologic malignancies, head and neck, breast and prostate cancer. Cell strains from multiple myelomas that have become growth factor independent require constitutively active Stat3 to protect against apoptosis. In addition, constitutively activated Stat3 induces cellular transformation in vitro. Stat3 participates in oncogenesis through up-regulation of genes encoding apoptosis inhibitors (Bcl-xL, Mcl-1 and survivin), cell-cycle regulators (cyclin D1 and c-Myc) and inducers of angiogenesis vascular endothelial growth factor (VEGF).
Stat3 is activated by phosphorylation at tyrosine residue 705 (Y705), which leads to dimer formation, its nuclear translocation, DNA binding and target gene transcription. Phosphorylation of Stat3 at tyrosine 705 (Y705) is critically its dimerization and nuclear translocation; both prerequisites of Stat3 activation. Thus, we considered that inhibiting this phosphorylation at residue 705 might reduce VEGF expression in tumor cells.
Thus, the Stat3 signaling pathway may represent a potential molecular target for novel therapeutic approaches for bladder cancer. As outlined below, Stat3 can be targeted at one or more steps. Strategies to target Stat3 include decreasing Stat3 levels, reducing tyrosine phosphorylation of Stat3 and receptor complexes, reducing Stat3 recruitment to receptor complexes and its dimerization, and reducing Stat3 binding to promoters. Studies have shown that using a variety of approaches, such as tyrosine kinase inhibitors such as tyrphostin AG490, Antisense oligonucleotides, decoy oligonucleotides, and dominant-nagative Stat3 proteins can inhibit Stat3 expression in cancer cells to surpress proliferation and induce apoptosis.
Small interfering RNA (siRNAs)are short doubles tranded RNA (dsRNA)Molecules that can target complementary mRNAs for degradation via a Cellular process termed RNA interference (RNAi). RNAi is usually activated by introducing long double-stranded RNA molecules into cells which are cleaved into 21-nt to 23-nt RNAs referred to as siRNAs by an endonuclease named Dicer in animal cells. The siRNA molecules then serve as a guide for sequence-specific degradation of homologous mRNAs. siRNA has been used for functional analysis of genes in many species including invertebrates, plants, and mammalian cells. Recently, siRNA has emerged as powerful RNAi reagents for gene silencing and inhibition of viral propagation. The potential of using siRNA for silencing specific genes has been demonstrated in treatment of viral diseases and cancer.
At present, the primary limitation of cancer therapy is lack of selectivity of therapeutic agents for tumor cells. Current efforts are focused on discovering and developing anticancer agents that selectively target only tumor cells and spare normal tissue to improve the therapeutic index. It has been known that attenuated Salmonella typhimurium accumulate and replicate preferentially in tumors to a level that is 1,000-fold greater than found in cells from normal tissues. S. typhimurium is a facultative anaerobic bacterium, which is capable of replicating preferentially in tumor cells and inhibition of growth, is associated with lysis of tumors with a necrotic/hypoxic centre. These observations suggest that the tumor targeting bacteria in combination with other antitumor agents, represents a promising strategy for the treatment of primary and metastatic tumors.
The present study was designed to investigate the potentiall use of siRNA to block Stat3 expression, its efect on growth and apoptosis of human bladder cancer cells, and effect on tumor formation in Balb/c nude mice.We construct pSHlSi-Stat3 and transfected it in bladder cancer cells to observe its inhibition effect on Stat3 expression and its effect on growth, proliferation and apoptosis of bladder cancer cells T24. We further use attenuated S. typhimurium carrying Si-Stat3 to observe its therapeutic effect on nude mice transplantation tumor. Our results showed that targeting Stat3 signaling using siRNA technique may serve as a novel therapeutic Strategy for treatment of bladder cancer.
However, to our knowledge, no reports have been published to date concerning the effect of siRNA against the Stat3 gene in bladder cancers cells. In our studies we have used T24 bladder cancer cells, which have shown to be of value for the study of bladder cancer.
Study objectives:
(1) to determine if Stat3 siRNA can inhibit the expression of Stat3 gene in bladder cancer cells in vivo and in vitro.
(2) to explore that the attenuated S. typhimurium with siRNA-Stat3 plasmids were induced to primary tumor and subcutaneous transplantation tumor model for developing more effective treatment for bladder cancer.
Methods:
(1) Study on the Expression of Stat3, Survivin, VEGF in tissue of Bladder Transitional cell carcinoma and their Clinical Significances
(2) Construction of a recombinant plasmid expressing Stat3 siRNA
Using Stat3 gene sequences from GenBank, selected suitable target site,synthesized oligonucleotides as DNA template encoding Stat3 siRNA, annealed and ligated into pSilencer~(TM) neo3.1-H1 expression vector to construct plasmid pSilencer~(TM) neo3.1-H1-Stat3(pH1Si-Stat3, Si-Stat3).
(3) Studies in vitro:
The bladder cancer cell lines were transfected with plasmids pH1Si-Stat3. To determine the expression of the Stat3 at 72h after transfection, semi -quantitative RT-PCR analysis , Western blot and immunocytochemical detection analyses with the samples extracted from transfected and control cells were performed. The cells were also analyzed for cell cycle phase distribution and apoptosis rate by flow cytometry, and stained by acridine orange to detect the early apoptosis.MTT assay showed that the growth-inhibition rate of the Stat3 siRNA groups was significantly higher than that of the vehicle group or plasmid group.
(4) Studies in vivo:
To study the effects of pHlSi-Stat3 on bladder tumor growth in vivo, we developed a nude mouse tumor xenograft model.First of all, mice were transplanted via.s.c. with T24 cells into the left hip for tumor-bearing nude mice.Then the primary tumor and spontaneous metastasis mice models were established by surgical orthotopic implantation in nude mice. On day 14 and 21, palpable tumors had developed in the spontaneous metastasis mice models, and Attenuated S. typhimurmm carried Si-Stat3 or scramble plasmids were introduced via intratumor injection into the mice. On day 10 and 17, the primary metastasis bladder tumors had developed in the primary bladder cancer metastasis models of nude mice, and Attenuated S. typhimurmm carried Si-Stat3 or scramble plasmids were introduced via intraperitoneal injection into the mice.The HE staning was used to detect the level of the tumor tissues.The TUNEL assay was used to detect the apoptosis of tumor cells. RT-PCR and Western blot analysis were used to detect the expression levels of related genes and proteins. Immunohistochemistries for Stat3, VEGF, Survivin, Bcl-2 and Ki-67 were performed to determine the distribution of their related proteins.
Results:
(1) Stat3, Survivin,VEGF protein showed positive expression of 64%, 56% and 68% respectively in bladder cancer tissue than in normal bladder mucosa with statistical significience(p<0.01).The expression rate of Stat3, Survivin,VEGF were strongly correlated whit pathological grade and clinical statge of the TCC (P<0.01) . And these three factors were showed hightly negative correlation with prognosis of these patients(with p<0.01;p<0.01; p<0.05, respectively) .
(2) The plasmids pHlSi-Stat3 containing siRNA-Stat3 were constructed, and confirmed by restriction enzyme digest and sequence analysis.
(3) Transfection with pHlSi-Stat3 inhibited the growth of T24 cells and induced apoptosis effect for suppression of tumors. The results from semi-quantitative RT-PCR analysis, immunocytochemical detection and Western blot analyses for the samples from T24 cells after transfection with Si-Stat3, demonstrated that the plasmids containing Si-Stat3, could specifically reduce Stat3 expression. The Si-Stat3 transfected groups showed: (i) that the total Stat3 expression levels were not reduced, (ii) that the expression levels of Bcl-2, cyclin D1, survivin and VEGF were significantly depressed. The results of MTT, FCM and acridine orange detection assay demonstrated that the Si-Stat3 group showed remarkable apoptosis effects compared to untreated and scramble groups. Examination of subcutaneous tumors in nude mice showed that in the group transfected with Si-Stat3, both the average weights and volumes of the tumors were lower than those of other groups. The results indicated the effect for suppression of tumor growth by the siRNA-Stat3.
(4) Systemic administration of attenuated S. typhimurium carrying Si- Stat3 for bladder cancer therapy.
An animal model of bladder cancer demonstrating primary bladder tumor and subcutaneous metastasis by surgical orthotopic implantation in nude mice has been obtained. In primary bladder tumor model and subcutaneous metastasis bladder tumor model ,the group treated with attenuated S. typhimurium carrying Si-Stat3 and Si-scramble plasmids introduced via. intratumor injection or via intraperitoneal injection showed selectively growth suppression of tumors compared with untreated and Si-Scramble groups, respectively. Average tumor weights and volumes in the mice treated with Si-Stat3 carried by Salmonella were significantly lower than the untreated and scramble groups. Average tumor weights and volumes in the scramble groups notable showed lower than that of the untreated. The tumor tissue cells developed apoptosis.
Conclusions:
(1) we successfully constructed pH1Si-Stat3 plasmid.
(2) In this studies, we show for the first time that a bladder cancer therapy with SiRNA-Stat3 showed a remarkable effect with respect to suppression of tumors in vitro and in a nude mice model, and Si-Stat3 which was carried by attenuated S. typhimurium showed significant suppression effect for primary transplanted tumor growth of bladder cancer. RNAi technique may be a promising tool for cancer therapy.
(3) Stat3 signaling pathway is an ideal molecule target to gene therapy of bladder cancer.
引文
1 Decker T,Kovarik P.Serine phosphorylation of STATs[J].Oncogene,2000;19(21):2628-2637.
2 Bromberg J.Stat proteins and oncogenesis[J].J Clin Invest,2002;109(9):1139-1142.
3 Bromberg JF,Wrzeszczynska MH,Devgan G,et al.Stat3 as an oncogene[J].Cell,1999;98(3):295-303.
4 Takahash i Y,kifadaiY,Bucana CD,et al.Expression of vascular endothelial growth factor and if is respect,KDR,Correlates with vascularity,metastasis and proliferat ion of Human colon cancer[J].Cancer Res,1995;55(9):3964-3968.
5 Folkman J.What is the evidence that tumor are angiogenesis dependent [J]? Cancer Inst,1990;82(1):4-11.
6 薛军,林茂芳.Survivin基因在血液肿瘤细胞株细胞的表达[J].实用肿瘤杂志,2003,(06):453-456.
7 Ling Zhang,Lifang Gao,Lijuan Zhao,et al.Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs[J].Cancer Res.2007;67(12):59-64.
8 Lifang Gao,Ling Zhang,Jiadi Hu,et al.Down-regulation of signal transducer and activator of transcription3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J].Clin Cancer Res,2005;11(17):63 33-6341.
9 Bowman T,Garcia R,Turkson J,et al.STATs in oncogenesis[J].Oncogene.2000,19:2474-2488.
10 Turkson J,Bowman T,Garcia R,et al.STAT3 activation by src induced specific gene regulation and is required for cell transformation[J].Mol Cell Biol,1998,18(5):2545-2552.
11 Bromberg J F,Horvath CM,Besser D,et al.Stat3 activation in required for cellular transformation by v-src[J].Mol Cell Biol,1998,18(5):2553-2558.
12 Biethan S,Alves F,Wilde S,et al.Expression of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in nomal granulopoiesis and in blast cells of acute myelogenous leukemia[J].Exp Hematol,1999,27(5):885-894.
13 Dhir R,Ni Z,Lou W,et al.Stat3 activation in prostatic carcinomas[J].Prostate,2002,51(4):241-246.
14 NiZ,Lou W,Leman ES,et al.Inhibition of constitutively activated STAT3signaling pathway suppresses growth of prostate cancer cells[J].Cancer Res,2000,60(5):1225-1228
15 Turner KJ,Crew JP,Wykoff CC,et al.The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer[J]. Br J cancer, 2002, 86(8): 1276-1282.
16 Pavlichenko OV, Shatskaia VA, Luzai EV. The molecular mechanism responsible for the adaptation of malignant tumors to hormonal drugs: a role of phosphatidylinositol-3-kinase and phosphoinositide-dependent proteins [J] . Vestn Ross Akad Med Nauk, 2004; 12; 20-5.
17 Ferrara N. VEGF as a therapeutic target in cancer. Oncology[J],(2005)69(suppl. 3):11—16.
18 Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor lalpha[J]. Genes Dev, 2000, 14(1): 34-44.
19 Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells[J]. Oncogene, 2004, 23(28): 4921-4929.
20 Tran J, Rak J, Sheehan C,et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells[J]. Biochem Biophys Res Commun. 1999;264 (3):781- 788.
21 Kishi H, Igawa M, Kikuno N. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis[J]. Urology, 2004, 171(5) :1855-1860.
22 Fromont G, Chene L, Vidaud M, et al. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR[J]. Int J Cancer, 2005,114 (2):174-181.
23 Sah NK, Khana Z, Khana GJ, et al. Structural, functional and therapeutic biology of survivin[J]. Cancer Letters, 2006, 244(2): 164-171.
24 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res 2002; 8:945-954.
1 Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of that stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo[J]. Proc Natl Acad Sci USA, 2000;97:42 27-32.
2 Sharp PA, Zamore PD. Molecular biology: RNA interference [J]. Science,2000;287:2431-3.
3 Schulz WA. Understanding urothelial carcinoma through cancer pathways [J]. Int J Cancer, 2006, 119(7): 1513 — 1518.
4 Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53,cyclin DI, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder [J]. Int J Radiat Oncol Biol Phys, 2001, 49(5): 1305-1310.
5 Weinberg RA. E2F and cell proliferation: a world turned upside down [J].Cell 1996, 85(4): 457-459.
6 Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J]. Nat Genet, 1999,23(1): 18-20.
7 Sherr CJ. Cancer cell cycles [J]. Science, 1996, 274: 1672-1677.
8 Lifang Gao, Ling Zhang, Jiadi Hu, et al. Down-regulation of signal transducer and activator of transcription3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J]. Clin Cancer Res, 2005; 11(17): 6333-41.
9 Zhang L, Gao LF, Zhao LJ, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs[J]. Cancer Res. 2007; 67(12): 59-64.
10 Elbashir S, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001;411:494-8.
11 Bromberg JF,Wrzeszczynska MH,Devgan G,et al.STAT3 as an oncogene[J].Cell,1999;98:295-303.
12 Catlett-Falcone R,Landowski TH,Oshiro MM,et al.Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells[J].Immunity,1999;10:105-15.
13 Burdelya L,Kujawski M,Niu G,et al.Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects[J].Immunity,2005;7:3925-31.
14 Leong PL,Andrew GA,Johnson DE,et al.Targeted inhibition of STAT3with a decoy oligonucleotide abrogates head and neck cancer cell growth[J].Proc Natl Acad Sci USA,2003;100:4138-43.
15 Garcia R,Bowman TL,Niu G,et al.Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells[J].Oncogene,2001;20:2499-513.
16 Lopez-Beltran A,Cheng L,Andersson L,et al.Preneoplastic non-papillary lesions and conditions of the urinary bladder:an update based an the Ancna International Consultatin[J].Virchows Arch,2002,40(1):3-11.
17 陈志强,位志峰,叶章群,杨为民。腺性膀胱炎中肿瘤相关指标的改变和临床分型的探讨。中华医学杂志,2005,85(26):1842-1844.
18 Hayashibara T,Yamada Y,Miyanishi T,et al.Vascular endothelial growth factor and cellular chemotaxis:a possible autocrine pathway in adult T-cell leukemia cell invasion[J].Clin Cancer Res,2001,7(9):2719-2726.
19 Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 a.[J]Genes Dev,2000,14(1):34-44.
20 Niu G,et al.Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis[J]. Oncogene ,2002 21:2000-2008.
21 Kasschau KD,Carrington JC. A counterdefensive strategy of plantviruses: suppression of posttranscriptional gene silencing. Cell. 1998 ;95(4):461-70.
22 Plasterk R H. RNA silencing: the genome's immune system. Science.2002 May17; 296(5571): 1263-1265.
23 Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo[J]. Nat Biotechnol, 2002; 20(10): 1006-1010.
24 Maeda I , Kohara Y, Yamamoto M , et al. Large scale analysis of gene function in Caenorhabditis elegans by high throughput RNAi. .Curr Biol ,2001; 11 (3): 1712-1716.
25 Yin JQ , Wan Y. RNA mediated gene regulation systemmow and the future. Int J Mol Med, 2002; 10 (4) :355-365.
26 Lin S L, Chuong C M, IingS Y A. Novelm RNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys ResCommun. 2001 Mar2; 281(3): 639-644.
27 Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cell streated with siRNA, a primer of RNA interference Oncogene.2002 Sep5;21(39):6041-6048.
28 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res 2002; 8:945-954.
1 Killion,J.J.,Radinsky,R.and Fidler,I.J.:Orthotopic models are necessary to predict therapy of transplantable rumors in mice[J].Cancer Metastasis Rev,17:279,1998.
2 Togo,S.,Shimada,H.,Kubota,T.,Moossa,A.R.and Hoffman,R.M.:Host organ specifically determines cancer progression[J].Cancer Res,55:681,1995.
3 Chen JQ,Zhan WH,He YL,et al.Expression of heparanase gene,CD44v6,MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas [J]. World J Gastroenterol, 2004, 10(6):776-782.
4 Yamada Y, Hamajima N, Kato T, et al. Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer [J]. J Mol Med,2003, 81(2): 126-131.
5 CoferP J, Koenderman L,d e GrootR P.T he role ofS tats in myeloid Differentiation and leukemia. Oncogene, 2000,19(21 ):2511 -2522.
6 LinT S,M ahajanS ,FrankD A.Stat signaling in the pathogenesis and treatment of leukemias. O ncogene,2000,19 (21):2496-2504.
7 Huang M, Page C, Reynold RK, et al. Constitutive activation of Stat3 oncogene product in human ovarian carcinoma cells.G y necol Oncol. 2000,79(1):67-3.
8 Song JI,Grandis JR. Stat signaling in head and neck cancer. Oncogene 2000,19(21):2489-2495.
9 Garcia R, Bowman T L, N iuG, et al. Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participate sin growth regulation of human breast carcinoma cells. Oncogene, 2001, 20(20):2499-2513.
10 Schaefer LK, Ren Z , Fuller G N, et al. Constitutive activation of Stat3 alpha in bra in tumors: Localization to tumor endothelial cells and activation by the end othelial tyrosine kinase receptor (VEGFR-2).Oncogene,2002,21(13):2058-2065.
11 Lou W , N I Z , Dyer K ,et al. Interleukin-6 induces prostate cancer cell growth acompanied by activation of stat3 signaling pathway. Prostate.2000 ,42 (3):239-242.
12 Troussard AA, Costello P, Yoganathan TN, et al. The integrin linked kinase ( ILK) induces an invasive phenotype via AP-I transcription factor-dependent up regulation of matrix metalloproeinase 9 (MMP29 ) [ J ].Oncogene, 2000, 19 ( 48 ): 5444-5452.
13 Wu C, Keightley SY, Leung2Hagesteijn C. Integrin-linked protein kinase regulates fibronectin matrix assembly, E2cadherin expression, and tumorigenicity[ J ]. J Biol Chem, 1998, 273 (1): 528-536.
14 Grandis J R, G renning S D, C hakraborty A , et al. Requirements of Stat3 but not Stat 1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest, 1998,102(7): 1385-1392.
15 Burke WM, Jin X, Lin HJ et al. Inhibition of constitutively active STAT3 suppresses growth of human ovarian and breast cancer cell . Ongene,2001,20(55):7925-7934
16 Konnikova L , Kotecki M , Kruger MM , et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells [J ] .BMC Cancer ,2003 ,3 :23.
17 Gao L ,Zhang L ,Zhao X ,et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J ] .Clin Cancer Res ,2005 ,11 (17) :6333-41.
18 Novina C D, Murray M F, .N at Med Dykxhoorn DM, et al. siRNA directed inhibition of HI V-1 infection . Nat Med , 2002,8 (7):681-686.
19 McCafrey A P, N akaiH , Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology, 2003, 21(6): 639-644.
20 Seo MY, A brignani S, Houghton M , et al. Small interferencing RNA mediated inhibition of hepatitis C virus replication in the human hepatoma celline Huh-7. J Viro 1, 2003, 77 (1): 810-812.
21 Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo[J]. Nat Biotechnol, 2002,20(10): 1006-1010.
22 Cespedes MV, Casanowa I, Parreno M, et al. Mouse model in oncogenesis and cancer therapy . J Clin Transl Oncol, 2006,8(5 ):318-329.
23 Hoffman RM. Orthotopic isorthodox: why are orthotopic-transplant rnetastaticmodels different from all othermodels? J Cell Biochem.1994;56(1): 1-3.
24 Fu X, Hoffman RM. Human ovarian carcinoma metastasis models constructed in nudemice by orthotopic transplantation of histologically intactpatient specimens. Anticancer Res, 1993; 13(2): 283-6.
25 Grubbs CJ,Lubet RA, Koki AT, et al. Celeconxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344-rats J.Cancer Res,2000,60(20):5599-5602.
26 Bohle A , Jurczok A, Ardelt P ,et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo[J].Urol,2002,167(l):357-363.
27 Kikuchi E , Xu S, Ohori M, et al . Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic Resonance Imaging [J]. Urol, 2003, 170(4, Part 1 of 2), pp 1375-1378.
28 Bisson JF , Parache RM, Droulle P ,et al . A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer ,2002 , 102(3) :280 - 285.
29 Gary SO , Yu C ,Thomas J ,et al. A model of bladder tumor xenografts in the nude rat [J].Urol ,1995 ,154 (5):1925 - 1929.
30 Nakamura K, Fujiyama C , Tokuda Y, et al . Bladder cancer cell implantation in reconstructed bladder in vitro :a model of tumour recurrence[J]. BJU Int ,2002 ,89(1):119 - 125.
31 Giinther JH , Jurczok A , Wulf T ,et al . Optimizing syngenetic orthotopic murine bladder cancer (MB49)[J]. Cancer Res , 1999 , 59 ( 12) : 2834-2837.
32 Manzotti, C, Audisio, R. A. and Pratesi, G: Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis, 11:5, 1993.
33 Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference[J] .Nat Genet,2003,33(3) :401-406.
34 Hall AH, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in Hela cells[J]. J Virol, 2003,77(10):6066-9.
35 Lieberman J, Song E, Lee SK, et al. Interfering with disease:opportunities and roadblocks to harnessing RNA interference [J].Trends Mol,Med,2003,9: 397-403.
36 Eermudes D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors[J]. Curr Opin Drug Discov Devel,2002,5(2): 194-199.
37 King I, Bermues D, Lin 5, et al. Tumor-targeted Sulmonella expressing cytosine deaminase as an anticancer agent[J]. Hum Gene Ther, 2002,13(10):225-33.
38 John M. Pawelek, K. Brooks Low, David Bermudes. Tumor-targeted Salmonella as a Novel Anticancer Vector, Cancer Res, Oct 1997; 57:4537-4544.
3 Zheng LM, Luo M, Fens M, et al Tumor amplified protein expression therapy: Salmonella as a tumor selective protein delivery vector[J].Oncol Res,2000,12:127-135.
40 Jain KK. Use of bacteria as anticancer agents[ J].Expert Opin Biol Therap,001,l(2):291-300.
41 Kochi SK, Killeen KP, Pyan US, et al. Advances in the development of bacterial vector[J]. Expert Rev Vaccine, 2003,2( 1 ):31 -43.
42 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[.T]. Clin Cancer Res 2002; 8:945-954.
1. Ihle J N. STATs: STATs: signal transducers and activators of transcription.Cell, 1996, 84(3): 331-334.
2. Darnell JE Jr. STATs and gene regulation Science, 1997, 277(5332):1630-1635.
3. Chakraborty A, Tweardy DJ. STAT3 and G-CSF-induced myeloid differentiation Leuk Lymphoma, 1998, 30(5-6): 433-442.
4. Koji Itahana, Ying Zou, Yoko Itahana, Jose-Luis Martinez, Christian Beausejour, Jacqueline J. L. Jacobs, Maarten van Lohuizen, Vimla Band,Judith Campisi, and Goberdhan P. Dimri. Control of the Replicative Life Span of Human Fibroblasts by p16 and the Polycomb Protein Bmi-1. Mol.Cell. Biol, 2003, 23 (1): 389-401.
5. RamanaC V,Chatterjee-Kishore M ,Nguyen H ,StarkG R.Complex roles of Stats in regulating gene expression.Oncogene, 2000,19(21): 2619-2627.
6. LinJ X, LeonardW J.The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene, 2000, 19(21): 2566-2576.
7. HiranoT, Ishihara K, Hibi M.Roles of STAT3 in mediating the cell growth,differentiation, and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19(21): 2548-2556.
8. Smithgall T E, Briggs S D,Schreiner S,et al.Control of myeloid differentiation and survival by Stats.Oncogene,2000,19(21): 2612-2618.
9. MuiA L.The role of STATs in proliferation, differentiation and apoptosis.Cell MotLifeSci, 1999,55(12): 1547-1558.
10. Levy DE et al. J Clin Invest, 2002, 109 (9): 1143-1148
11. Huang M, Page C, Reynold R K, et a 1. Constitutive activation of Stat3 oncogene product in human ovarian carcinoma cells.Gynecoloncol. 2000,79 (1):673.
12.Bowman T,Garcia R,Trukson J,et al.STATs in oncogenesis[J]Oncogene,2000:19:2474-2488.
13.CoferP J,Koenderman L,De Groot R P.The role of Stats in myeloid Differentiation and leukemia.Oncogene,2000,19(21):2511-2522.
14.LinT S,MahajanS,Frank D A.Stat signaling in the pathogenesis and treatment of leukemias.Oncogene,2000,19(21):2496-2504.
15.Song J I,G randisJ R.Star signaling in head and neck cancer.Oncogene 2000,19(21):2489-2495.
16.GarciaR,BowmanT L,et al.Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participates in growth regulation of human breast carcinoma cells.Oncogene,2001,20(20):2499-2513.
17.SchaeferL K,Ren Z,Fuller G N,et al.Constitutive activation of Stat3alpha in brain tumors:Localization to tumor endothelial cells and activation by the end ot hel ial tyrosine kinase receptor(VEGFR-2).Oncogene,2002,21(13):2058-2065.
18.Lou W,NI Z,Dyer K,et al.Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway.Prostate.2000 42(3):239-242.
19.马向涛,王杉,叶颖江,等.Stat3及其靶基因产物与结直肠癌恶性程度关系的研究[J].癌症,2003,22(11):1135-1139.
20.Caldenhoven E,van Dijk TB,Solari R,et al.STAT3beta,a splice variant of transcription factor STAT3,is a dominant negative regulator of transcription.[J]Bio Chem,1996,271(22):13221-13227.
21.Bromberg J F,Wrzeszczynska M H,Devgan G,et al.Stat3 as an oncogene.Cell,1999,98(3):295-303.
22.Kisseleva T,Bhattacharya S,Braunstein,J et al.Signaling through the JAK/STAT pathway,recent advances and future changes[J].Gene,2002,285(1-2),1-24.
23. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors p rovides novel molecular targets for therapeutic intervention [J]. Clin Cancer Res,2002, 8(4): 945-954.
24. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity, 1999, 10(1): 39-49.
25. Hiroaki Kodama, Keiichi Fukuda, Jing Pan, Motoaki Sano, Toshiyuki Takahashi, Takahiro Kato, Shinji Makino, Tomohiro Manabe, Mitsushige Murata, and Satoshi Ogawa. Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.Am J Physiol Heart Circ Physiol, Oct 2000; 279: H1635-H1644.
26. Arup Chakraborty, Kevin F. Dyer, Michael Cascio, Timothy A Mietzner and David J Tweardy. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor,Blood, Jan 1999; 93: 15-24.
27. Heinrich P.C., Behrmann I., Muller-Newen G.,et a 1. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway 1 Biochem [J].1998, l;334(Pt 2): 297-314.
28. Boeuf H., Hauss C, Graeve F.D., et a 1. Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells. J Cell Biol. 1997,138(6): 1207-17.
29. Niwa, H., Burdon, T, Chambers, I., and Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.Genes Dev. 1998, 12(13): 2048-60.
30. Raz, R., Lee, C.K., Cannizzaro, L.A., et a 1. Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Proc Natl Acad Sci U S A. 1999;96(6): 2846-51.
31. Matsuda, T., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999,18(15):4261-4269.
32. Hirano, T., Ishihara, K., and Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19(21): 2548-2556.
33. Regina R,Chien KL, Linda A, et al. Essential role of Stat3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA, 1999, 96(3): 2486-2851.
34. Boccaccio, C, Ando M, Tamagnone L et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998,391(6664): 285-8.
35. McLemore ML, Grewal S, Liu F, et al STAT3 activation is required for normal G-CSF dependent proliferation and granulocytic differentiation .Immunity. 2001, 14(2): 193-204.
36. Riley J K, Takeda, K. Akira, S.and Schreiber, R.D. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway Requirement for two distinct receptor- derived signals for anti-inflammatory action. J Biol Chem. 1999,274(23): 16513-21.
37. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3(9): 651-662
38. Dirk Remus, Marco Blanchette, Donald C. Rio, and Michael R. Botchan. CDK Phosphorylation Inhibits the DNA-binding and ATP-hydrolysis Activities of the Drosophila Origin Recognition Complex. [J] Biol. Chem,Dec 2005; 280: 39740-39751.
39. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 1994, 79(4): 573-582.
40. Loic Le Marchand, Ann Seifried, Annette Lum-Jones, Timothy Donlon,and Lynne R. Wilkens. Association of the Cyclin D1 A870G Polymorphism With Advanced Colorectal Cancer. JAMA, Dec 2003; 290:2843-2848.Sherr C J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 2000, 60(14): 3689-3695.
41. Adel K. Ayed and Aaron Adesina. INSTITUTIONAL REPORT-THORACIC GENERAL: Prognostic significance of cyclin D1 expression in resected stage I, II non-small cell lung cancer in Arabs. Interactive Cardiovascular and Thoracic Surgery, Feb 2006; 5: 47-51.
42. Zauberman A, Zipori D, Krupsky M, et al. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3.Oncogene, 1999, 18(26): 3886-3893
43. Scott Ely, Maurizio Di Liberto, Ruben Niesvizky, Eunice Hatada, Hearn Cho, Daniel M. Knowles, Joseph Lane, and Selina Chen-Kiang. Mutually Exclusive Cdk4-Cyclin Dl and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 501.
44.. Yeh TC, Pellegrini S. the Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci, 1999, 55(12): 1523-1534
45. Komemeyer SJ. Bcl-2: an antidote to programmed cell death [J]. Cancer Surv, 1992, 15: 105-18.
46. AmbrosiniG, Adida C,Altier DC,et al. A novel anti-apoptosis gene,surviving expressed in cancer and lymphoma [J].Nat Med, 1997; 3:917-21.
47. Altieri DC. The molecular basis and potential role of surviving in cancer diagnosis and therapy [J].Trends Mol Med, 2001; 7: 542-7.
48. Carvalho A, Cannena M, Sambade C, et al. Survivin is required for stable checkpoint activation in taxol-treated Hela cells [J].J Cell Sci, 2003; 116:2987-98.
49. Zaffaroni Z, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions [J]. Cell Mol, 2005; 9(2): 360-72.
50. Tamm I, Wang Y, Sausville E , et al . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998, 58 (23):5315-5320.
51. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivinn in human and mouse differentiation [J]. Am J Patol, 1998; 152(1): 43-9.
52. Tanaka K, Iwarmoto S, Gon G, et al. Expression of surviving and relationship to loss of apoptosis in breast carcinomas [J].Clin Cancer Res,2000; 6(2): 127-34.
53. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the anti-apoptosis gene, surviving, predects death from recurrent colorectal carcinoma [J]. Gut, 2000; 46: 645-50.
54. McEleny KR, Watson RW, Coffey RN, et al. Inhibitors of apoptosis proteins in prostate cancer cell lines [J]. Prostate, 2002; 51(2): 133-40.
55. Smith SD, Wheeler MA, Plesca J, et al. Urinc detection of Survivin and diagnosis of bladder cancer [J]. JAMA, 2001, 285(3): 324-328.
56. Whitney Salz, Dan Eisenberg, Janet Plescia, et al. A Survivin Gene Signature Predicts Aggressive Tumor Behavior. Cancer Research 2005; 65:3531-3534.
57. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survivial in association with surviving expression in gastric cancer cells. Oncogene, 2004, 23(28): 4921-4929.
58. Luscher B, Eisenman R N. New light on Myc and Myb [J]. Genes Dev,1990, 4(12B): 2235-41.
59. Chin Y E, Kitagawa M, Su WC, et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.Science, 1996, 272(5262): 719-722.
60. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.Proc Natl Acad Sci U S A, 2000, 97(8): 4227-4232.
61. Lu Q L, Poulsom R, Wong L, et al. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. [J] Pathol, 1993, 169(4): 431-437.
62. Nakopoulou L, Vourlakou C, Zervas A, et al. The revalence of Bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their Clinico pathologic correlates [J]. Hum Pathol, 1998, 29: 146-154.
63. Vollmer R T, Humphrey P A, Swanson P E, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2 [J]. Cancer, 1998, 82(4): 715-723.
64. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res, 1999, 59(7 Suppl): 1693s-1700s.
65.Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res, 1998, 58(2): 256-262.
66. Raffo A J, Perlman H, Chen M W, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res, 1995, 55(19): 4438-4445.
67. Nicosia R F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol, 1998, 153(1): 11-16.
68. Folkman J. What is the evidence that tumor are angiogenesis dependent? Cancer Inst, 1990, 82 (1): 4-11.
69. Takahash i Y, kifadaiY, Bucana CD, et al. Expressionof vascular endothelial growth factor and if is respect, KDR, Correlates with vascularity, metastasis and proliferation of Human colon cancer. Cancer Res, 1995, 55 (9): 3964-3968.
70. Borgstrom P, Bourdon M A, Hillan K J, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 1998,35(1): 1-10.
71. Jung J E, Lee H G, Cho I H, et al. STAT3 is a potential modulator of HIF-1- mediated VEGF expression in human renal carcinoma cells.FASEB [J], 2005, 19(10): 1296-1298.
72. Crew J P , Obrien T , Bicknell R , et al . Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rate. [J] Urol, 1999, 161 : 799-804.
73. Ogura Y, Sato K, Kato T , et al. Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superfical bladder cancer. Nippon Hinyokika GaKKai Zasshi. 1998 ,89: 529-537.
74. Mukhopadhyay, Debabrata, Tsiokas, Leonidas, Zhou, Xiao-Mai, Foster,David, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. London: Jun 15, 1995.Vol. 375, Iss. 6532; p. 577
75. Turkson J, Bowman T, GarciaR ,et al .STAT3 activation by Src induced specific gene regulation and is required for cell transformation. Mot Cell Biol. 1998, 18(5): 2545-2552.
76. Jacqueline F B, Melissa H, Wrzeszczynska B, et a 1. Stat3 as an oncogene. Cell. 1999, 98(8): 295-303.
77. Ephng-Burnete P K, LiuJ H, Catlet-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and Decreased Mcl-1 expression. [J] Clin Invest, 2001, 107(3): 351-362.
78. Bromerg J F, HorvathC M, Besser D, et al. Stat3 activation is reauired for cellular transformation by v-src. Mot Cell Biol, 1998, 18(5): 2553-2558.
79. Catlet-Falcone R, Landowski TH, O shiroM M, et al. Constitute activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10 (1): 105-115.
80. Watson C J. STAT transcription factors in mammary gland development and tumorigenesis. [J] Mammary Gland Biol Neoplasia, 2001, 6(1):115-127.
81. Kube D, Holtick U, Vockerodt M, et a 1. Stat3 is constitutively activated in Hodgkin cell lines. Blood, 2001, 98(3): 762-770.
82. Niu Q, Wright K L, Huang M, e ta l.C onstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.Oncogene, 2002,21(13): 2000-2008.
83. Konnikova L, Kotecki M, kruger M M, et al. Knochdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells [J]. BMC Cancer, 2003,3:23.
84. Burke WM, Jin X, Lin HJ et al. Inhibition of constitutively active STAT3 suppresses growth of human ovarian and breast cancer cell. Ongene, 2001.20(55):7925-7934.
85. Grandis J R, Grenning S D, Chakraborty A, et a 1. Requirements of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J C linInvest, 1998, 102(7): 1385-1392.
86. Roy Garcia, Tammy L Bowman, Guilian Niu, Hua Yu, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene. Basingstoke:May 3, 2001. Vol. 20, Iss, 20; p. 2499-2513.
87. Guilian Niu, Kenneth H. Shain, Mei Huang, Rajani Ravi, Atul Bedi,William S. Dalton, Richard Jove, and Hua Yu. Overexpression of a Dominant-Negative Signal Transducer and Activator of Transcription 3 Variant in Tumor Cells Leads to Production of SolubleFactors That Induce Apoptosis and Cell Cycle Arrest. Cancer Res Apr 2001; 61(8): 3276-3280.
88.James Turkson, Declan Ryan, Joon S. Kim, Yi Zhang, Zhi Chen. Eric Haura, Andy Laudano, Said Sebti, Andrew D. Hamilton, and Richard Jove. Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity,Gene Regulation,and Cell Transformation[J]Biol Chem,2001,276(48):45443-45455.
89.Femandes A,Hamburger AW,Gerwin BI.ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells.Int J Cancer.1999,83(4):564-570.
90.刘忠良,刘禄成,张国成等.抗人膀胱癌/抗VEGF双功能基因抗体的动物实验研究.中国老年学杂志,2005;(25):563-565.
91.Tim O' Brien,David Cranston,Susan Fuggle,Roy Bicknell,and Adrian L.Harris.Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer.Cancer Res,Feb 1995;55(3):510-513.
92.Jeremy P.Crew,Tim O'Brien,Mike Bradburn,Sue Fuggle,Roy Bicknell,David Cranston,and Adrian L.Harris.Vascular Endothelial Growth Factor Is a Predictor of Relapse and Stage Progression in Superficial Bladder Cancer.Cancer Res,Dec 1997;57:5281-5285.
93.Kasschau K D,Carrington J C.A counter defensive strategy of plant viruses:suppression of post transcriptional gene silencing.Cell.1998;95(4):461-470.
94.Napoli C,Lemienx C,Jorgensen R,Introduction of a Chimeric chalcone synthase gene into Pemmia results in reversible co-suppression of homologous genes in trans.Plant cell,1990,2(4):279-289.
95.Cogoni C,Romano N,Macino G.Suppressionof gene expression by homologus transgenes[J]AntonieVan Leeuwenhoek,1994,65(3):205-209
96.Su Guo.Kemphues KJ.Part Ⅰ,a gene required for establishing polarity in C.elegans,encodes a putative Ser/Thr kinase that is asymmetrically distributed cell,1995;81(5):611-620.
97.Wu-Scharf D,Jeong B,Zhang C Ceruti H.Transgene and transposon silencing in Chlamydomonas reinhardtii by a DEAH-box RNA helicase. Science.2000 Nov10; 290(5494): 1159-1162.
98. Dalmay T, Hamilton A, Rudd S, Angell S, Baulcombe DC. An RNA-dependent RNA polymerase gene in Arabidopsisis required for post transcriptional gene silencing mediated by a transgene but not by a virus.Cell Biology 2000May26; 101(5):554-553.
99. Emily Bernstein, Caudy A A, Hammond SM, Harmon G1 Role for a bidentate ribonuclease in the initiation step of RNA interference Nature.2001 Jan 18; 409(68 18): 363-366.
100. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha 1, Baillie DL,Fire A, Ru vkun q Mello C C.Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C.elegans developmental timing.Cell. 2001 Jul13; 106(1): 23-34.
101.Emily Bernstein, Sang Yong Kim, Michelle A Carmell, Elizabeth P Murchison, et a 1. Dicer is essential for mouse development. Nature Genetics, New York: Nov2003. Vol.35, Iss 3; p215.
102.Florence Wianny, Magdalena Zernicka-Geotz. Specific interference with gene function by double-stranded RNA in early mouse development Nature Cell Biology Lodon Feb2000 Vol2, Iss 2; pg.70.
103.P.Svoboda. Long dsRNA and silent genes strike back: RNAi in mouse oocytes and early embryos.Cytogenetic and Genome Research.Basel:2004.Vol. 105, Iss,2-4,pg 422.
104.Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. et a 1 . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411 (6836): 494-498.
105.Urano F, Calfon M, Yoneda T, Yun C, Kiraly M, Clark SCE Ron D. A survival pathway for Caenor habditise legans with a blocked unfolded protein response J Cell Bio 1. 2002Augl9; 158(4): 639-646.
106.Li H , Li W X, DingS W. Induction and suppression of RNA silencing by an animal virus Science . 2002 May17; 296(5571): 1319-1321.
107.Lindenbach B D, Rice C M.RNAi targeting an animal virus: news from the front. MolCell, 2002May; 9(5): 925-927.
108.Smardon A, Spoerke J M, Stacey S C, Klein M E, Mackin N, Maine E M.EGG-1 is related to RNA-directed RNA polymerise and functions in germ-line development and RNA interferencein C .elegans. CurrBiol.2000 Feb 24; 10(4): 169- 178.
109.Plasterk R H. RNA silencing: the genome's immune system. Science.2002 May 17; 296(5571): 1263-1265.
110.Nykanen A, Haley B, Zamore P D. ATP requirements and small interfering RNA Structure in the RNA interference pathway. Cell.2001 Nov2; 107(3):309-321.
111 .Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T.Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002 Sep6; 110(5): 563-574.
112. Lipardi C, Wei Q, Paterson B M. RNAi as random degradative PCR:siRNA primers convert mRNA into dsRNAs that are degraded to generate Cell. 2001 Nov2; 107(3): 297-307.
113.Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods.2002 Feb; 26(2): 199-213.
114.Paddison P J, Caudy A A, HannonG J. Stable suppression of gene expression by RNAi in mammalian cells ProcNailAcadSci USA,2002Feb5;99(3): 1443-1448.
115.Svoboda P, Stein P, Hayashi H, Schultz RM. Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference.development. 2000 Oct; 127(19): 4147-4156.
116.Gonczy P, Echeverri C, Oegema K, Coulson A, Jones S J, Copley R R,Duperon J, Oegema J, Brehm M, Cassin E, Harmak E, Kirkham M,Pichler S, Flohrs K, Goessen A, Leidel S, Alleaume A M, Martin COzlu N, Bork P, HymanA A. Functional genomic analysis of cell division in C.elegans using RNAi of geneson chromosomel II. Nature.2000Nov16;408(6810):331-336.
117. Fraser A C, S KamathR S, Zipperlen P, Martinez-Campos M, Sohrmann M, A hringer J. Function algenomic analysis of C.elegans chromosomel by systematic RNA interference.Nature. 2000Novl6; 408(6810):325-330.
118.Lin S L, Chuong C M, IingS Y A. Novelm RNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys ResCommun. 2001 Mar2; 281(3): 639-644.
119Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cell streated with siRNA, a primer of RNA interference Oncogene.2002 Sep5;21(39):6041-6048.
120.Yin J Q, Gao J, Shao R, TianW N, Wang J, Wan Y. siRNA a gents inhibit oncogene expression and a tenuate human tumor cell growth. [J] ExpTherOncol. 2003 Jul-Aug; 3(4): 194-204.
121. McCafreyA P, Ohashi K, Meuse L, Shen S, Lancaster A M, Lukavsky P J,Samow P, Kay M A. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. MolTher.2002Jun; 5(6):676-684.
122. Capodici J, Kariko K, Weissman D. Inhibition of HIV1 infection by small interfering RNA-mediated RNA interference. [J] Immunol. 2002 Nov1;169(9): 5196-5201.
123.Coburn G A, Cullen B R. Potent and specific inhibition of human immuno deficiency virus typel replication by RNA interference. [J] Virol.2002Sep;76(18):9 225-231.
124.Ge Q, McManus M T, NguyenT ,ShenC H, SharpP A, E isenH N,C henJ .RNA interference of influenzavirus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. ProcNail Acad SciUSA. 2003Mar4; 100(5): 2718-2723.
125. Jia Q, SunR .Inhibition of gammaherpesvirus replication by RNAi nterference. [J] Viral .2003 Mar; 77(5): 3301-3306.
126. Valdes V J, Sampieri A, Sepulveda J,Vaca L. Using double-stranded RNA to Prevent in vitro and in vivo viral infections recombinant baculovirns. [J] BiolChem. 2003 May23; 278(21): 19317-19324.
127.Fire A, Xu S, Montgomery MK, et al. potent and specific genetic interference by double-strand RNA in Caenorhabditis elegans. Nature,1998; 391(6669): 806-811.
128. Thomas Tuschl. Expanding small RNA inference Nature Biotechnology New York: May 2002. Vol. 20, Iss. 5; p. 446.
129.Yi Pei, Thomas Tuschl. On the art of identifying effective and specific siRNAs. Nature Methods. New York: Sep 2006. Vol, 3, Iss 9; p. 670
130.Milligan J F. Groebe D R, Witherell G W. Uhlenbeck O C.Oligoribonucleotide Synthesis using T7 RNA polymerase and synthetic DNA templates NucleicAcidsRes. 1987Novll; 15(21): 8783-8798.
131.Knight S W, BassB L.A role for the RNaseIII enzyme DCR-1 in RNA Interference and germ line development in Caenorhabditise legans.Science. 2001 Sep21; 293 (5538): 2269-2271.
132.Suiq Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC, Shi Y A DNA vector -bas ed RNAi technology to suppress gene expression in mammalian cells. Proc. Natl.A cad.Sci.USA.2002, 99(8):5515-5520.
133.Brummelkamp TR, Bernards R, and Agami R. A system for stable expression of short interfering RNAs in mammalian cells Science 2002,296:550-553.
134.Paul C P, Good P D,Winer I and Engelke DR. Effective expression of small Interfering RNA in human cells. Nature Biotechnology2002,20:505-508.
135.Castanoto D, Li H, Rossi JJ. Functional siRNA expression from transfected PCR products RNA 2002, 8(11): 1454-1460.
136.O Greco, B Marples, G U Dachs, K J Williams, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation Gene Therapy. Houndmills: Oct 2002. Vol 9, Iss. 20: p. 1403.
137.Sirard JC, Niedergang F, Kraehenbuhl J P. Live attenuated Salmonlal:aparadigm of mucosal vaccines [J].Immunol Rev 1999, 171: 5-26.
138.Bermudas D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors [J] Curr Opion Drug Discov Devel, 2002, 5(2): 194-199.
13 9.Vazquez-Torres A, Fang FC. Cellular routes of invasion by enteropathogens, Curr Opin Microbiol, 2000, 3(1): 54-59.
140.Rescigno M, Urbano M, alzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol, 2001, 2(4):361-367.
141.Vazquez-Torres A, Jones-Carson J, BaumlerA J, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes, [J] Nature 1999,401 (6755): 804-808.
142.Grillot-Courvalin C, Gousard S, Huetz F, et al. Functional gene transfer from introcellar bacteria to mammalian cells [J] NatBiotechnol, 1998,16(9): 862-866.
143.Paglia P, Medina E, Arioli I, et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimuirum, results in protective immunity against a murine fibrosarcoma [J].Blood 1998, 92(9):3172-3176.
144.Flo J, Tisminetzky S, Baralle F. Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. [J] Vaccine2001, 19(13-14): 1772-1782.
145.Lee CH, Wu CL, Shima, et al. Systemic administration of attenuated Salmonella choleraesuis carrying chrombosponding-1 gene leads to tumor specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model [J] . Cancer Gene Ther, 2005, 12(2): 175-184.
146.Dunja Bruder, Alexander K. Nussbaum, Dimitry M. Gakamsky, Markus Schirle, et al. Multiple synergizing factors contribute to the strength of the CD8~+T cell response against listeriolysin O.International Immunology.Oxford: Jan 2006. Vol 18, Iss. 1; p89.
147.Darji A, Lage S Z, Garbe A, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimuirum as carrier[J] FEMS Immunol MedMicrobiol 2000, 27(4): 341-349.
148.Woo P C, WongL P, ZhengB J, et al. Unique irnrnunogenicity of hepatitis B. virus DNA vaccine presented by live-atenuated Salmonella typhimuirum [J].Vaccine2001, 19(20-22): 2945-2954.
149.Khan CMA, Villarreal-Ramos B, Pierce RJ,.et al. Construction, expression and immunogenity of multiple tandem copies of the Schistosoma manosni pepitde 115- 131of the P28 glutathione, S-transferese expressed as C-terminal fusions to tetanus toxin fragment C in a line aro-attenuated vaccine strain of Salmonella [J]. Immunol,1994.153:5634.
150.Scinivasm J, Tinger S, Wringt R, et al. Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and reproductive tract [J]. Biol Reprnd, 1995, 53: 462.
151.John M. Pawelek, K. Brooks Low, David Bermudes. Tumor-targeted Salmonella as a Novel Anticancer Vector, Cancer Res, Oct 1997; 57:4537-4544.
152.Bermudas D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors [J] Curr Opion Drug Discov Devel, 2002, 5(2): 194-199.
153.Dietrich G, Kolb Maurer A, Spreng S, et al. Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines. Vaccine,2001, 19(17-19): 2506-2512.
154.Cochlovius B, Stassar MJ, Schreurs M W, et al. Oral DNA vaccination:antigen uptake and presentation by dendritic cells elicits protective immunity. ImmunolLett, 2002, 80(2): 89-96.
155.Yrlid U, WickM J. Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter. [J] Immunol, 2002, 169(1): 108-116.
156.Rescigno M, Granucci F, Citterio S, et al. Coordinate devents during bacteria- induced DC maturation. Immunol Today, 1999, 20(5): 200-203.
157.ShataM T, Stevceva L, Agwale S, et al. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today, 2000, 6(2): 66-71.
158.Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with supperessed virulence and TNF alpha induction retain tumor-targeting in vivo. Nat Biotechnol, 1999, 17(1): 37-41.
159.Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to Patients with Metastatic Molanoma [J]. J Clin Oncol, 2002, 20(1): 142-152.
160.Yrlid U, WickM J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antign after uptake by bystander dendritic cells [J]. J Exp Med 2000, 191(4): 613-624.
161.Paglia P, Terrazzini N, Schulze K, et al .In vivo correction of genetic defects of monocyte/macorphages using attenuated Salmonella as oral vectors for targeted gene delivery [J], Gene Ther 2000, 7(20): 1725-1730.
162.FeltisB A, SaharD A, Kim AS, et al .Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum, 2002, 45(8): 1023-1028.
163.Soto LJ 3rd, Soernson BS, Kim AS, et al. Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. [J] Pediatr Surg,2003,38(7): 1075-1079.
2 Bromberg J.Stat proteins and oncogenesis[J].J Clin Invest,2002;109(9):1139-1142.
3 Bromberg JF,Wrzeszczynska MH,Devgan G,et al.Stat3 as an oncogene[J].Cell,1999;98(3):295-303.
4 Takahash i Y,kifadaiY,Bucana CD,et al.Expression of vascular endothelial growth factor and if is respect,KDR,Correlates with vascularity,metastasis and proliferat ion of Human colon cancer[J].Cancer Res,1995;55(9):3964-3968.
5 Folkman J.What is the evidence that tumor are angiogenesis dependent [J]? Cancer Inst,1990;82(1):4-11.
6 薛军,林茂芳.Survivin基因在血液肿瘤细胞株细胞的表达[J].实用肿瘤杂志,2003,(06):453-456.
7 Ling Zhang,Lifang Gao,Lijuan Zhao,et al.Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs[J].Cancer Res.2007;67(12):59-64.
8 Lifang Gao,Ling Zhang,Jiadi Hu,et al.Down-regulation of signal transducer and activator of transcription3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J].Clin Cancer Res,2005;11(17):63 33-6341.
9 Bowman T,Garcia R,Turkson J,et al.STATs in oncogenesis[J].Oncogene.2000,19:2474-2488.
10 Turkson J,Bowman T,Garcia R,et al.STAT3 activation by src induced specific gene regulation and is required for cell transformation[J].Mol Cell Biol,1998,18(5):2545-2552.
11 Bromberg J F,Horvath CM,Besser D,et al.Stat3 activation in required for cellular transformation by v-src[J].Mol Cell Biol,1998,18(5):2553-2558.
12 Biethan S,Alves F,Wilde S,et al.Expression of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in nomal granulopoiesis and in blast cells of acute myelogenous leukemia[J].Exp Hematol,1999,27(5):885-894.
13 Dhir R,Ni Z,Lou W,et al.Stat3 activation in prostatic carcinomas[J].Prostate,2002,51(4):241-246.
14 NiZ,Lou W,Leman ES,et al.Inhibition of constitutively activated STAT3signaling pathway suppresses growth of prostate cancer cells[J].Cancer Res,2000,60(5):1225-1228
15 Turner KJ,Crew JP,Wykoff CC,et al.The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer[J]. Br J cancer, 2002, 86(8): 1276-1282.
16 Pavlichenko OV, Shatskaia VA, Luzai EV. The molecular mechanism responsible for the adaptation of malignant tumors to hormonal drugs: a role of phosphatidylinositol-3-kinase and phosphoinositide-dependent proteins [J] . Vestn Ross Akad Med Nauk, 2004; 12; 20-5.
17 Ferrara N. VEGF as a therapeutic target in cancer. Oncology[J],(2005)69(suppl. 3):11—16.
18 Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor lalpha[J]. Genes Dev, 2000, 14(1): 34-44.
19 Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells[J]. Oncogene, 2004, 23(28): 4921-4929.
20 Tran J, Rak J, Sheehan C,et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells[J]. Biochem Biophys Res Commun. 1999;264 (3):781- 788.
21 Kishi H, Igawa M, Kikuno N. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis[J]. Urology, 2004, 171(5) :1855-1860.
22 Fromont G, Chene L, Vidaud M, et al. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR[J]. Int J Cancer, 2005,114 (2):174-181.
23 Sah NK, Khana Z, Khana GJ, et al. Structural, functional and therapeutic biology of survivin[J]. Cancer Letters, 2006, 244(2): 164-171.
24 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res 2002; 8:945-954.
1 Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of that stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo[J]. Proc Natl Acad Sci USA, 2000;97:42 27-32.
2 Sharp PA, Zamore PD. Molecular biology: RNA interference [J]. Science,2000;287:2431-3.
3 Schulz WA. Understanding urothelial carcinoma through cancer pathways [J]. Int J Cancer, 2006, 119(7): 1513 — 1518.
4 Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53,cyclin DI, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder [J]. Int J Radiat Oncol Biol Phys, 2001, 49(5): 1305-1310.
5 Weinberg RA. E2F and cell proliferation: a world turned upside down [J].Cell 1996, 85(4): 457-459.
6 Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J]. Nat Genet, 1999,23(1): 18-20.
7 Sherr CJ. Cancer cell cycles [J]. Science, 1996, 274: 1672-1677.
8 Lifang Gao, Ling Zhang, Jiadi Hu, et al. Down-regulation of signal transducer and activator of transcription3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J]. Clin Cancer Res, 2005; 11(17): 6333-41.
9 Zhang L, Gao LF, Zhao LJ, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs[J]. Cancer Res. 2007; 67(12): 59-64.
10 Elbashir S, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001;411:494-8.
11 Bromberg JF,Wrzeszczynska MH,Devgan G,et al.STAT3 as an oncogene[J].Cell,1999;98:295-303.
12 Catlett-Falcone R,Landowski TH,Oshiro MM,et al.Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells[J].Immunity,1999;10:105-15.
13 Burdelya L,Kujawski M,Niu G,et al.Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects[J].Immunity,2005;7:3925-31.
14 Leong PL,Andrew GA,Johnson DE,et al.Targeted inhibition of STAT3with a decoy oligonucleotide abrogates head and neck cancer cell growth[J].Proc Natl Acad Sci USA,2003;100:4138-43.
15 Garcia R,Bowman TL,Niu G,et al.Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells[J].Oncogene,2001;20:2499-513.
16 Lopez-Beltran A,Cheng L,Andersson L,et al.Preneoplastic non-papillary lesions and conditions of the urinary bladder:an update based an the Ancna International Consultatin[J].Virchows Arch,2002,40(1):3-11.
17 陈志强,位志峰,叶章群,杨为民。腺性膀胱炎中肿瘤相关指标的改变和临床分型的探讨。中华医学杂志,2005,85(26):1842-1844.
18 Hayashibara T,Yamada Y,Miyanishi T,et al.Vascular endothelial growth factor and cellular chemotaxis:a possible autocrine pathway in adult T-cell leukemia cell invasion[J].Clin Cancer Res,2001,7(9):2719-2726.
19 Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 a.[J]Genes Dev,2000,14(1):34-44.
20 Niu G,et al.Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis[J]. Oncogene ,2002 21:2000-2008.
21 Kasschau KD,Carrington JC. A counterdefensive strategy of plantviruses: suppression of posttranscriptional gene silencing. Cell. 1998 ;95(4):461-70.
22 Plasterk R H. RNA silencing: the genome's immune system. Science.2002 May17; 296(5571): 1263-1265.
23 Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo[J]. Nat Biotechnol, 2002; 20(10): 1006-1010.
24 Maeda I , Kohara Y, Yamamoto M , et al. Large scale analysis of gene function in Caenorhabditis elegans by high throughput RNAi. .Curr Biol ,2001; 11 (3): 1712-1716.
25 Yin JQ , Wan Y. RNA mediated gene regulation systemmow and the future. Int J Mol Med, 2002; 10 (4) :355-365.
26 Lin S L, Chuong C M, IingS Y A. Novelm RNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys ResCommun. 2001 Mar2; 281(3): 639-644.
27 Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cell streated with siRNA, a primer of RNA interference Oncogene.2002 Sep5;21(39):6041-6048.
28 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res 2002; 8:945-954.
1 Killion,J.J.,Radinsky,R.and Fidler,I.J.:Orthotopic models are necessary to predict therapy of transplantable rumors in mice[J].Cancer Metastasis Rev,17:279,1998.
2 Togo,S.,Shimada,H.,Kubota,T.,Moossa,A.R.and Hoffman,R.M.:Host organ specifically determines cancer progression[J].Cancer Res,55:681,1995.
3 Chen JQ,Zhan WH,He YL,et al.Expression of heparanase gene,CD44v6,MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas [J]. World J Gastroenterol, 2004, 10(6):776-782.
4 Yamada Y, Hamajima N, Kato T, et al. Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer [J]. J Mol Med,2003, 81(2): 126-131.
5 CoferP J, Koenderman L,d e GrootR P.T he role ofS tats in myeloid Differentiation and leukemia. Oncogene, 2000,19(21 ):2511 -2522.
6 LinT S,M ahajanS ,FrankD A.Stat signaling in the pathogenesis and treatment of leukemias. O ncogene,2000,19 (21):2496-2504.
7 Huang M, Page C, Reynold RK, et al. Constitutive activation of Stat3 oncogene product in human ovarian carcinoma cells.G y necol Oncol. 2000,79(1):67-3.
8 Song JI,Grandis JR. Stat signaling in head and neck cancer. Oncogene 2000,19(21):2489-2495.
9 Garcia R, Bowman T L, N iuG, et al. Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participate sin growth regulation of human breast carcinoma cells. Oncogene, 2001, 20(20):2499-2513.
10 Schaefer LK, Ren Z , Fuller G N, et al. Constitutive activation of Stat3 alpha in bra in tumors: Localization to tumor endothelial cells and activation by the end othelial tyrosine kinase receptor (VEGFR-2).Oncogene,2002,21(13):2058-2065.
11 Lou W , N I Z , Dyer K ,et al. Interleukin-6 induces prostate cancer cell growth acompanied by activation of stat3 signaling pathway. Prostate.2000 ,42 (3):239-242.
12 Troussard AA, Costello P, Yoganathan TN, et al. The integrin linked kinase ( ILK) induces an invasive phenotype via AP-I transcription factor-dependent up regulation of matrix metalloproeinase 9 (MMP29 ) [ J ].Oncogene, 2000, 19 ( 48 ): 5444-5452.
13 Wu C, Keightley SY, Leung2Hagesteijn C. Integrin-linked protein kinase regulates fibronectin matrix assembly, E2cadherin expression, and tumorigenicity[ J ]. J Biol Chem, 1998, 273 (1): 528-536.
14 Grandis J R, G renning S D, C hakraborty A , et al. Requirements of Stat3 but not Stat 1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest, 1998,102(7): 1385-1392.
15 Burke WM, Jin X, Lin HJ et al. Inhibition of constitutively active STAT3 suppresses growth of human ovarian and breast cancer cell . Ongene,2001,20(55):7925-7934
16 Konnikova L , Kotecki M , Kruger MM , et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells [J ] .BMC Cancer ,2003 ,3 :23.
17 Gao L ,Zhang L ,Zhao X ,et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo[J ] .Clin Cancer Res ,2005 ,11 (17) :6333-41.
18 Novina C D, Murray M F, .N at Med Dykxhoorn DM, et al. siRNA directed inhibition of HI V-1 infection . Nat Med , 2002,8 (7):681-686.
19 McCafrey A P, N akaiH , Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology, 2003, 21(6): 639-644.
20 Seo MY, A brignani S, Houghton M , et al. Small interferencing RNA mediated inhibition of hepatitis C virus replication in the human hepatoma celline Huh-7. J Viro 1, 2003, 77 (1): 810-812.
21 Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo[J]. Nat Biotechnol, 2002,20(10): 1006-1010.
22 Cespedes MV, Casanowa I, Parreno M, et al. Mouse model in oncogenesis and cancer therapy . J Clin Transl Oncol, 2006,8(5 ):318-329.
23 Hoffman RM. Orthotopic isorthodox: why are orthotopic-transplant rnetastaticmodels different from all othermodels? J Cell Biochem.1994;56(1): 1-3.
24 Fu X, Hoffman RM. Human ovarian carcinoma metastasis models constructed in nudemice by orthotopic transplantation of histologically intactpatient specimens. Anticancer Res, 1993; 13(2): 283-6.
25 Grubbs CJ,Lubet RA, Koki AT, et al. Celeconxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344-rats J.Cancer Res,2000,60(20):5599-5602.
26 Bohle A , Jurczok A, Ardelt P ,et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo[J].Urol,2002,167(l):357-363.
27 Kikuchi E , Xu S, Ohori M, et al . Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic Resonance Imaging [J]. Urol, 2003, 170(4, Part 1 of 2), pp 1375-1378.
28 Bisson JF , Parache RM, Droulle P ,et al . A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer ,2002 , 102(3) :280 - 285.
29 Gary SO , Yu C ,Thomas J ,et al. A model of bladder tumor xenografts in the nude rat [J].Urol ,1995 ,154 (5):1925 - 1929.
30 Nakamura K, Fujiyama C , Tokuda Y, et al . Bladder cancer cell implantation in reconstructed bladder in vitro :a model of tumour recurrence[J]. BJU Int ,2002 ,89(1):119 - 125.
31 Giinther JH , Jurczok A , Wulf T ,et al . Optimizing syngenetic orthotopic murine bladder cancer (MB49)[J]. Cancer Res , 1999 , 59 ( 12) : 2834-2837.
32 Manzotti, C, Audisio, R. A. and Pratesi, G: Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis, 11:5, 1993.
33 Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference[J] .Nat Genet,2003,33(3) :401-406.
34 Hall AH, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in Hela cells[J]. J Virol, 2003,77(10):6066-9.
35 Lieberman J, Song E, Lee SK, et al. Interfering with disease:opportunities and roadblocks to harnessing RNA interference [J].Trends Mol,Med,2003,9: 397-403.
36 Eermudes D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors[J]. Curr Opin Drug Discov Devel,2002,5(2): 194-199.
37 King I, Bermues D, Lin 5, et al. Tumor-targeted Sulmonella expressing cytosine deaminase as an anticancer agent[J]. Hum Gene Ther, 2002,13(10):225-33.
38 John M. Pawelek, K. Brooks Low, David Bermudes. Tumor-targeted Salmonella as a Novel Anticancer Vector, Cancer Res, Oct 1997; 57:4537-4544.
3 Zheng LM, Luo M, Fens M, et al Tumor amplified protein expression therapy: Salmonella as a tumor selective protein delivery vector[J].Oncol Res,2000,12:127-135.
40 Jain KK. Use of bacteria as anticancer agents[ J].Expert Opin Biol Therap,001,l(2):291-300.
41 Kochi SK, Killeen KP, Pyan US, et al. Advances in the development of bacterial vector[J]. Expert Rev Vaccine, 2003,2( 1 ):31 -43.
42 Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention[.T]. Clin Cancer Res 2002; 8:945-954.
1. Ihle J N. STATs: STATs: signal transducers and activators of transcription.Cell, 1996, 84(3): 331-334.
2. Darnell JE Jr. STATs and gene regulation Science, 1997, 277(5332):1630-1635.
3. Chakraborty A, Tweardy DJ. STAT3 and G-CSF-induced myeloid differentiation Leuk Lymphoma, 1998, 30(5-6): 433-442.
4. Koji Itahana, Ying Zou, Yoko Itahana, Jose-Luis Martinez, Christian Beausejour, Jacqueline J. L. Jacobs, Maarten van Lohuizen, Vimla Band,Judith Campisi, and Goberdhan P. Dimri. Control of the Replicative Life Span of Human Fibroblasts by p16 and the Polycomb Protein Bmi-1. Mol.Cell. Biol, 2003, 23 (1): 389-401.
5. RamanaC V,Chatterjee-Kishore M ,Nguyen H ,StarkG R.Complex roles of Stats in regulating gene expression.Oncogene, 2000,19(21): 2619-2627.
6. LinJ X, LeonardW J.The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene, 2000, 19(21): 2566-2576.
7. HiranoT, Ishihara K, Hibi M.Roles of STAT3 in mediating the cell growth,differentiation, and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19(21): 2548-2556.
8. Smithgall T E, Briggs S D,Schreiner S,et al.Control of myeloid differentiation and survival by Stats.Oncogene,2000,19(21): 2612-2618.
9. MuiA L.The role of STATs in proliferation, differentiation and apoptosis.Cell MotLifeSci, 1999,55(12): 1547-1558.
10. Levy DE et al. J Clin Invest, 2002, 109 (9): 1143-1148
11. Huang M, Page C, Reynold R K, et a 1. Constitutive activation of Stat3 oncogene product in human ovarian carcinoma cells.Gynecoloncol. 2000,79 (1):673.
12.Bowman T,Garcia R,Trukson J,et al.STATs in oncogenesis[J]Oncogene,2000:19:2474-2488.
13.CoferP J,Koenderman L,De Groot R P.The role of Stats in myeloid Differentiation and leukemia.Oncogene,2000,19(21):2511-2522.
14.LinT S,MahajanS,Frank D A.Stat signaling in the pathogenesis and treatment of leukemias.Oncogene,2000,19(21):2496-2504.
15.Song J I,G randisJ R.Star signaling in head and neck cancer.Oncogene 2000,19(21):2489-2495.
16.GarciaR,BowmanT L,et al.Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participates in growth regulation of human breast carcinoma cells.Oncogene,2001,20(20):2499-2513.
17.SchaeferL K,Ren Z,Fuller G N,et al.Constitutive activation of Stat3alpha in brain tumors:Localization to tumor endothelial cells and activation by the end ot hel ial tyrosine kinase receptor(VEGFR-2).Oncogene,2002,21(13):2058-2065.
18.Lou W,NI Z,Dyer K,et al.Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway.Prostate.2000 42(3):239-242.
19.马向涛,王杉,叶颖江,等.Stat3及其靶基因产物与结直肠癌恶性程度关系的研究[J].癌症,2003,22(11):1135-1139.
20.Caldenhoven E,van Dijk TB,Solari R,et al.STAT3beta,a splice variant of transcription factor STAT3,is a dominant negative regulator of transcription.[J]Bio Chem,1996,271(22):13221-13227.
21.Bromberg J F,Wrzeszczynska M H,Devgan G,et al.Stat3 as an oncogene.Cell,1999,98(3):295-303.
22.Kisseleva T,Bhattacharya S,Braunstein,J et al.Signaling through the JAK/STAT pathway,recent advances and future changes[J].Gene,2002,285(1-2),1-24.
23. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors p rovides novel molecular targets for therapeutic intervention [J]. Clin Cancer Res,2002, 8(4): 945-954.
24. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity, 1999, 10(1): 39-49.
25. Hiroaki Kodama, Keiichi Fukuda, Jing Pan, Motoaki Sano, Toshiyuki Takahashi, Takahiro Kato, Shinji Makino, Tomohiro Manabe, Mitsushige Murata, and Satoshi Ogawa. Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.Am J Physiol Heart Circ Physiol, Oct 2000; 279: H1635-H1644.
26. Arup Chakraborty, Kevin F. Dyer, Michael Cascio, Timothy A Mietzner and David J Tweardy. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor,Blood, Jan 1999; 93: 15-24.
27. Heinrich P.C., Behrmann I., Muller-Newen G.,et a 1. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway 1 Biochem [J].1998, l;334(Pt 2): 297-314.
28. Boeuf H., Hauss C, Graeve F.D., et a 1. Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells. J Cell Biol. 1997,138(6): 1207-17.
29. Niwa, H., Burdon, T, Chambers, I., and Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.Genes Dev. 1998, 12(13): 2048-60.
30. Raz, R., Lee, C.K., Cannizzaro, L.A., et a 1. Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Proc Natl Acad Sci U S A. 1999;96(6): 2846-51.
31. Matsuda, T., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999,18(15):4261-4269.
32. Hirano, T., Ishihara, K., and Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19(21): 2548-2556.
33. Regina R,Chien KL, Linda A, et al. Essential role of Stat3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA, 1999, 96(3): 2486-2851.
34. Boccaccio, C, Ando M, Tamagnone L et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998,391(6664): 285-8.
35. McLemore ML, Grewal S, Liu F, et al STAT3 activation is required for normal G-CSF dependent proliferation and granulocytic differentiation .Immunity. 2001, 14(2): 193-204.
36. Riley J K, Takeda, K. Akira, S.and Schreiber, R.D. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway Requirement for two distinct receptor- derived signals for anti-inflammatory action. J Biol Chem. 1999,274(23): 16513-21.
37. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3(9): 651-662
38. Dirk Remus, Marco Blanchette, Donald C. Rio, and Michael R. Botchan. CDK Phosphorylation Inhibits the DNA-binding and ATP-hydrolysis Activities of the Drosophila Origin Recognition Complex. [J] Biol. Chem,Dec 2005; 280: 39740-39751.
39. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 1994, 79(4): 573-582.
40. Loic Le Marchand, Ann Seifried, Annette Lum-Jones, Timothy Donlon,and Lynne R. Wilkens. Association of the Cyclin D1 A870G Polymorphism With Advanced Colorectal Cancer. JAMA, Dec 2003; 290:2843-2848.Sherr C J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 2000, 60(14): 3689-3695.
41. Adel K. Ayed and Aaron Adesina. INSTITUTIONAL REPORT-THORACIC GENERAL: Prognostic significance of cyclin D1 expression in resected stage I, II non-small cell lung cancer in Arabs. Interactive Cardiovascular and Thoracic Surgery, Feb 2006; 5: 47-51.
42. Zauberman A, Zipori D, Krupsky M, et al. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3.Oncogene, 1999, 18(26): 3886-3893
43. Scott Ely, Maurizio Di Liberto, Ruben Niesvizky, Eunice Hatada, Hearn Cho, Daniel M. Knowles, Joseph Lane, and Selina Chen-Kiang. Mutually Exclusive Cdk4-Cyclin Dl and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 501.
44.. Yeh TC, Pellegrini S. the Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci, 1999, 55(12): 1523-1534
45. Komemeyer SJ. Bcl-2: an antidote to programmed cell death [J]. Cancer Surv, 1992, 15: 105-18.
46. AmbrosiniG, Adida C,Altier DC,et al. A novel anti-apoptosis gene,surviving expressed in cancer and lymphoma [J].Nat Med, 1997; 3:917-21.
47. Altieri DC. The molecular basis and potential role of surviving in cancer diagnosis and therapy [J].Trends Mol Med, 2001; 7: 542-7.
48. Carvalho A, Cannena M, Sambade C, et al. Survivin is required for stable checkpoint activation in taxol-treated Hela cells [J].J Cell Sci, 2003; 116:2987-98.
49. Zaffaroni Z, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions [J]. Cell Mol, 2005; 9(2): 360-72.
50. Tamm I, Wang Y, Sausville E , et al . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998, 58 (23):5315-5320.
51. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivinn in human and mouse differentiation [J]. Am J Patol, 1998; 152(1): 43-9.
52. Tanaka K, Iwarmoto S, Gon G, et al. Expression of surviving and relationship to loss of apoptosis in breast carcinomas [J].Clin Cancer Res,2000; 6(2): 127-34.
53. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the anti-apoptosis gene, surviving, predects death from recurrent colorectal carcinoma [J]. Gut, 2000; 46: 645-50.
54. McEleny KR, Watson RW, Coffey RN, et al. Inhibitors of apoptosis proteins in prostate cancer cell lines [J]. Prostate, 2002; 51(2): 133-40.
55. Smith SD, Wheeler MA, Plesca J, et al. Urinc detection of Survivin and diagnosis of bladder cancer [J]. JAMA, 2001, 285(3): 324-328.
56. Whitney Salz, Dan Eisenberg, Janet Plescia, et al. A Survivin Gene Signature Predicts Aggressive Tumor Behavior. Cancer Research 2005; 65:3531-3534.
57. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survivial in association with surviving expression in gastric cancer cells. Oncogene, 2004, 23(28): 4921-4929.
58. Luscher B, Eisenman R N. New light on Myc and Myb [J]. Genes Dev,1990, 4(12B): 2235-41.
59. Chin Y E, Kitagawa M, Su WC, et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.Science, 1996, 272(5262): 719-722.
60. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.Proc Natl Acad Sci U S A, 2000, 97(8): 4227-4232.
61. Lu Q L, Poulsom R, Wong L, et al. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. [J] Pathol, 1993, 169(4): 431-437.
62. Nakopoulou L, Vourlakou C, Zervas A, et al. The revalence of Bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their Clinico pathologic correlates [J]. Hum Pathol, 1998, 29: 146-154.
63. Vollmer R T, Humphrey P A, Swanson P E, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2 [J]. Cancer, 1998, 82(4): 715-723.
64. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res, 1999, 59(7 Suppl): 1693s-1700s.
65.Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res, 1998, 58(2): 256-262.
66. Raffo A J, Perlman H, Chen M W, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res, 1995, 55(19): 4438-4445.
67. Nicosia R F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol, 1998, 153(1): 11-16.
68. Folkman J. What is the evidence that tumor are angiogenesis dependent? Cancer Inst, 1990, 82 (1): 4-11.
69. Takahash i Y, kifadaiY, Bucana CD, et al. Expressionof vascular endothelial growth factor and if is respect, KDR, Correlates with vascularity, metastasis and proliferation of Human colon cancer. Cancer Res, 1995, 55 (9): 3964-3968.
70. Borgstrom P, Bourdon M A, Hillan K J, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 1998,35(1): 1-10.
71. Jung J E, Lee H G, Cho I H, et al. STAT3 is a potential modulator of HIF-1- mediated VEGF expression in human renal carcinoma cells.FASEB [J], 2005, 19(10): 1296-1298.
72. Crew J P , Obrien T , Bicknell R , et al . Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rate. [J] Urol, 1999, 161 : 799-804.
73. Ogura Y, Sato K, Kato T , et al. Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superfical bladder cancer. Nippon Hinyokika GaKKai Zasshi. 1998 ,89: 529-537.
74. Mukhopadhyay, Debabrata, Tsiokas, Leonidas, Zhou, Xiao-Mai, Foster,David, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. London: Jun 15, 1995.Vol. 375, Iss. 6532; p. 577
75. Turkson J, Bowman T, GarciaR ,et al .STAT3 activation by Src induced specific gene regulation and is required for cell transformation. Mot Cell Biol. 1998, 18(5): 2545-2552.
76. Jacqueline F B, Melissa H, Wrzeszczynska B, et a 1. Stat3 as an oncogene. Cell. 1999, 98(8): 295-303.
77. Ephng-Burnete P K, LiuJ H, Catlet-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and Decreased Mcl-1 expression. [J] Clin Invest, 2001, 107(3): 351-362.
78. Bromerg J F, HorvathC M, Besser D, et al. Stat3 activation is reauired for cellular transformation by v-src. Mot Cell Biol, 1998, 18(5): 2553-2558.
79. Catlet-Falcone R, Landowski TH, O shiroM M, et al. Constitute activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10 (1): 105-115.
80. Watson C J. STAT transcription factors in mammary gland development and tumorigenesis. [J] Mammary Gland Biol Neoplasia, 2001, 6(1):115-127.
81. Kube D, Holtick U, Vockerodt M, et a 1. Stat3 is constitutively activated in Hodgkin cell lines. Blood, 2001, 98(3): 762-770.
82. Niu Q, Wright K L, Huang M, e ta l.C onstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.Oncogene, 2002,21(13): 2000-2008.
83. Konnikova L, Kotecki M, kruger M M, et al. Knochdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells [J]. BMC Cancer, 2003,3:23.
84. Burke WM, Jin X, Lin HJ et al. Inhibition of constitutively active STAT3 suppresses growth of human ovarian and breast cancer cell. Ongene, 2001.20(55):7925-7934.
85. Grandis J R, Grenning S D, Chakraborty A, et a 1. Requirements of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J C linInvest, 1998, 102(7): 1385-1392.
86. Roy Garcia, Tammy L Bowman, Guilian Niu, Hua Yu, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene. Basingstoke:May 3, 2001. Vol. 20, Iss, 20; p. 2499-2513.
87. Guilian Niu, Kenneth H. Shain, Mei Huang, Rajani Ravi, Atul Bedi,William S. Dalton, Richard Jove, and Hua Yu. Overexpression of a Dominant-Negative Signal Transducer and Activator of Transcription 3 Variant in Tumor Cells Leads to Production of SolubleFactors That Induce Apoptosis and Cell Cycle Arrest. Cancer Res Apr 2001; 61(8): 3276-3280.
88.James Turkson, Declan Ryan, Joon S. Kim, Yi Zhang, Zhi Chen. Eric Haura, Andy Laudano, Said Sebti, Andrew D. Hamilton, and Richard Jove. Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity,Gene Regulation,and Cell Transformation[J]Biol Chem,2001,276(48):45443-45455.
89.Femandes A,Hamburger AW,Gerwin BI.ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells.Int J Cancer.1999,83(4):564-570.
90.刘忠良,刘禄成,张国成等.抗人膀胱癌/抗VEGF双功能基因抗体的动物实验研究.中国老年学杂志,2005;(25):563-565.
91.Tim O' Brien,David Cranston,Susan Fuggle,Roy Bicknell,and Adrian L.Harris.Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer.Cancer Res,Feb 1995;55(3):510-513.
92.Jeremy P.Crew,Tim O'Brien,Mike Bradburn,Sue Fuggle,Roy Bicknell,David Cranston,and Adrian L.Harris.Vascular Endothelial Growth Factor Is a Predictor of Relapse and Stage Progression in Superficial Bladder Cancer.Cancer Res,Dec 1997;57:5281-5285.
93.Kasschau K D,Carrington J C.A counter defensive strategy of plant viruses:suppression of post transcriptional gene silencing.Cell.1998;95(4):461-470.
94.Napoli C,Lemienx C,Jorgensen R,Introduction of a Chimeric chalcone synthase gene into Pemmia results in reversible co-suppression of homologous genes in trans.Plant cell,1990,2(4):279-289.
95.Cogoni C,Romano N,Macino G.Suppressionof gene expression by homologus transgenes[J]AntonieVan Leeuwenhoek,1994,65(3):205-209
96.Su Guo.Kemphues KJ.Part Ⅰ,a gene required for establishing polarity in C.elegans,encodes a putative Ser/Thr kinase that is asymmetrically distributed cell,1995;81(5):611-620.
97.Wu-Scharf D,Jeong B,Zhang C Ceruti H.Transgene and transposon silencing in Chlamydomonas reinhardtii by a DEAH-box RNA helicase. Science.2000 Nov10; 290(5494): 1159-1162.
98. Dalmay T, Hamilton A, Rudd S, Angell S, Baulcombe DC. An RNA-dependent RNA polymerase gene in Arabidopsisis required for post transcriptional gene silencing mediated by a transgene but not by a virus.Cell Biology 2000May26; 101(5):554-553.
99. Emily Bernstein, Caudy A A, Hammond SM, Harmon G1 Role for a bidentate ribonuclease in the initiation step of RNA interference Nature.2001 Jan 18; 409(68 18): 363-366.
100. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha 1, Baillie DL,Fire A, Ru vkun q Mello C C.Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C.elegans developmental timing.Cell. 2001 Jul13; 106(1): 23-34.
101.Emily Bernstein, Sang Yong Kim, Michelle A Carmell, Elizabeth P Murchison, et a 1. Dicer is essential for mouse development. Nature Genetics, New York: Nov2003. Vol.35, Iss 3; p215.
102.Florence Wianny, Magdalena Zernicka-Geotz. Specific interference with gene function by double-stranded RNA in early mouse development Nature Cell Biology Lodon Feb2000 Vol2, Iss 2; pg.70.
103.P.Svoboda. Long dsRNA and silent genes strike back: RNAi in mouse oocytes and early embryos.Cytogenetic and Genome Research.Basel:2004.Vol. 105, Iss,2-4,pg 422.
104.Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. et a 1 . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411 (6836): 494-498.
105.Urano F, Calfon M, Yoneda T, Yun C, Kiraly M, Clark SCE Ron D. A survival pathway for Caenor habditise legans with a blocked unfolded protein response J Cell Bio 1. 2002Augl9; 158(4): 639-646.
106.Li H , Li W X, DingS W. Induction and suppression of RNA silencing by an animal virus Science . 2002 May17; 296(5571): 1319-1321.
107.Lindenbach B D, Rice C M.RNAi targeting an animal virus: news from the front. MolCell, 2002May; 9(5): 925-927.
108.Smardon A, Spoerke J M, Stacey S C, Klein M E, Mackin N, Maine E M.EGG-1 is related to RNA-directed RNA polymerise and functions in germ-line development and RNA interferencein C .elegans. CurrBiol.2000 Feb 24; 10(4): 169- 178.
109.Plasterk R H. RNA silencing: the genome's immune system. Science.2002 May 17; 296(5571): 1263-1265.
110.Nykanen A, Haley B, Zamore P D. ATP requirements and small interfering RNA Structure in the RNA interference pathway. Cell.2001 Nov2; 107(3):309-321.
111 .Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T.Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002 Sep6; 110(5): 563-574.
112. Lipardi C, Wei Q, Paterson B M. RNAi as random degradative PCR:siRNA primers convert mRNA into dsRNAs that are degraded to generate Cell. 2001 Nov2; 107(3): 297-307.
113.Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods.2002 Feb; 26(2): 199-213.
114.Paddison P J, Caudy A A, HannonG J. Stable suppression of gene expression by RNAi in mammalian cells ProcNailAcadSci USA,2002Feb5;99(3): 1443-1448.
115.Svoboda P, Stein P, Hayashi H, Schultz RM. Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference.development. 2000 Oct; 127(19): 4147-4156.
116.Gonczy P, Echeverri C, Oegema K, Coulson A, Jones S J, Copley R R,Duperon J, Oegema J, Brehm M, Cassin E, Harmak E, Kirkham M,Pichler S, Flohrs K, Goessen A, Leidel S, Alleaume A M, Martin COzlu N, Bork P, HymanA A. Functional genomic analysis of cell division in C.elegans using RNAi of geneson chromosomel II. Nature.2000Nov16;408(6810):331-336.
117. Fraser A C, S KamathR S, Zipperlen P, Martinez-Campos M, Sohrmann M, A hringer J. Function algenomic analysis of C.elegans chromosomel by systematic RNA interference.Nature. 2000Novl6; 408(6810):325-330.
118.Lin S L, Chuong C M, IingS Y A. Novelm RNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys ResCommun. 2001 Mar2; 281(3): 639-644.
119Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cell streated with siRNA, a primer of RNA interference Oncogene.2002 Sep5;21(39):6041-6048.
120.Yin J Q, Gao J, Shao R, TianW N, Wang J, Wan Y. siRNA a gents inhibit oncogene expression and a tenuate human tumor cell growth. [J] ExpTherOncol. 2003 Jul-Aug; 3(4): 194-204.
121. McCafreyA P, Ohashi K, Meuse L, Shen S, Lancaster A M, Lukavsky P J,Samow P, Kay M A. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. MolTher.2002Jun; 5(6):676-684.
122. Capodici J, Kariko K, Weissman D. Inhibition of HIV1 infection by small interfering RNA-mediated RNA interference. [J] Immunol. 2002 Nov1;169(9): 5196-5201.
123.Coburn G A, Cullen B R. Potent and specific inhibition of human immuno deficiency virus typel replication by RNA interference. [J] Virol.2002Sep;76(18):9 225-231.
124.Ge Q, McManus M T, NguyenT ,ShenC H, SharpP A, E isenH N,C henJ .RNA interference of influenzavirus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. ProcNail Acad SciUSA. 2003Mar4; 100(5): 2718-2723.
125. Jia Q, SunR .Inhibition of gammaherpesvirus replication by RNAi nterference. [J] Viral .2003 Mar; 77(5): 3301-3306.
126. Valdes V J, Sampieri A, Sepulveda J,Vaca L. Using double-stranded RNA to Prevent in vitro and in vivo viral infections recombinant baculovirns. [J] BiolChem. 2003 May23; 278(21): 19317-19324.
127.Fire A, Xu S, Montgomery MK, et al. potent and specific genetic interference by double-strand RNA in Caenorhabditis elegans. Nature,1998; 391(6669): 806-811.
128. Thomas Tuschl. Expanding small RNA inference Nature Biotechnology New York: May 2002. Vol. 20, Iss. 5; p. 446.
129.Yi Pei, Thomas Tuschl. On the art of identifying effective and specific siRNAs. Nature Methods. New York: Sep 2006. Vol, 3, Iss 9; p. 670
130.Milligan J F. Groebe D R, Witherell G W. Uhlenbeck O C.Oligoribonucleotide Synthesis using T7 RNA polymerase and synthetic DNA templates NucleicAcidsRes. 1987Novll; 15(21): 8783-8798.
131.Knight S W, BassB L.A role for the RNaseIII enzyme DCR-1 in RNA Interference and germ line development in Caenorhabditise legans.Science. 2001 Sep21; 293 (5538): 2269-2271.
132.Suiq Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC, Shi Y A DNA vector -bas ed RNAi technology to suppress gene expression in mammalian cells. Proc. Natl.A cad.Sci.USA.2002, 99(8):5515-5520.
133.Brummelkamp TR, Bernards R, and Agami R. A system for stable expression of short interfering RNAs in mammalian cells Science 2002,296:550-553.
134.Paul C P, Good P D,Winer I and Engelke DR. Effective expression of small Interfering RNA in human cells. Nature Biotechnology2002,20:505-508.
135.Castanoto D, Li H, Rossi JJ. Functional siRNA expression from transfected PCR products RNA 2002, 8(11): 1454-1460.
136.O Greco, B Marples, G U Dachs, K J Williams, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation Gene Therapy. Houndmills: Oct 2002. Vol 9, Iss. 20: p. 1403.
137.Sirard JC, Niedergang F, Kraehenbuhl J P. Live attenuated Salmonlal:aparadigm of mucosal vaccines [J].Immunol Rev 1999, 171: 5-26.
138.Bermudas D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors [J] Curr Opion Drug Discov Devel, 2002, 5(2): 194-199.
13 9.Vazquez-Torres A, Fang FC. Cellular routes of invasion by enteropathogens, Curr Opin Microbiol, 2000, 3(1): 54-59.
140.Rescigno M, Urbano M, alzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol, 2001, 2(4):361-367.
141.Vazquez-Torres A, Jones-Carson J, BaumlerA J, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes, [J] Nature 1999,401 (6755): 804-808.
142.Grillot-Courvalin C, Gousard S, Huetz F, et al. Functional gene transfer from introcellar bacteria to mammalian cells [J] NatBiotechnol, 1998,16(9): 862-866.
143.Paglia P, Medina E, Arioli I, et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimuirum, results in protective immunity against a murine fibrosarcoma [J].Blood 1998, 92(9):3172-3176.
144.Flo J, Tisminetzky S, Baralle F. Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. [J] Vaccine2001, 19(13-14): 1772-1782.
145.Lee CH, Wu CL, Shima, et al. Systemic administration of attenuated Salmonella choleraesuis carrying chrombosponding-1 gene leads to tumor specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model [J] . Cancer Gene Ther, 2005, 12(2): 175-184.
146.Dunja Bruder, Alexander K. Nussbaum, Dimitry M. Gakamsky, Markus Schirle, et al. Multiple synergizing factors contribute to the strength of the CD8~+T cell response against listeriolysin O.International Immunology.Oxford: Jan 2006. Vol 18, Iss. 1; p89.
147.Darji A, Lage S Z, Garbe A, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimuirum as carrier[J] FEMS Immunol MedMicrobiol 2000, 27(4): 341-349.
148.Woo P C, WongL P, ZhengB J, et al. Unique irnrnunogenicity of hepatitis B. virus DNA vaccine presented by live-atenuated Salmonella typhimuirum [J].Vaccine2001, 19(20-22): 2945-2954.
149.Khan CMA, Villarreal-Ramos B, Pierce RJ,.et al. Construction, expression and immunogenity of multiple tandem copies of the Schistosoma manosni pepitde 115- 131of the P28 glutathione, S-transferese expressed as C-terminal fusions to tetanus toxin fragment C in a line aro-attenuated vaccine strain of Salmonella [J]. Immunol,1994.153:5634.
150.Scinivasm J, Tinger S, Wringt R, et al. Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and reproductive tract [J]. Biol Reprnd, 1995, 53: 462.
151.John M. Pawelek, K. Brooks Low, David Bermudes. Tumor-targeted Salmonella as a Novel Anticancer Vector, Cancer Res, Oct 1997; 57:4537-4544.
152.Bermudas D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors [J] Curr Opion Drug Discov Devel, 2002, 5(2): 194-199.
153.Dietrich G, Kolb Maurer A, Spreng S, et al. Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines. Vaccine,2001, 19(17-19): 2506-2512.
154.Cochlovius B, Stassar MJ, Schreurs M W, et al. Oral DNA vaccination:antigen uptake and presentation by dendritic cells elicits protective immunity. ImmunolLett, 2002, 80(2): 89-96.
155.Yrlid U, WickM J. Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter. [J] Immunol, 2002, 169(1): 108-116.
156.Rescigno M, Granucci F, Citterio S, et al. Coordinate devents during bacteria- induced DC maturation. Immunol Today, 1999, 20(5): 200-203.
157.ShataM T, Stevceva L, Agwale S, et al. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today, 2000, 6(2): 66-71.
158.Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with supperessed virulence and TNF alpha induction retain tumor-targeting in vivo. Nat Biotechnol, 1999, 17(1): 37-41.
159.Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to Patients with Metastatic Molanoma [J]. J Clin Oncol, 2002, 20(1): 142-152.
160.Yrlid U, WickM J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antign after uptake by bystander dendritic cells [J]. J Exp Med 2000, 191(4): 613-624.
161.Paglia P, Terrazzini N, Schulze K, et al .In vivo correction of genetic defects of monocyte/macorphages using attenuated Salmonella as oral vectors for targeted gene delivery [J], Gene Ther 2000, 7(20): 1725-1730.
162.FeltisB A, SaharD A, Kim AS, et al .Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum, 2002, 45(8): 1023-1028.
163.Soto LJ 3rd, Soernson BS, Kim AS, et al. Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. [J] Pediatr Surg,2003,38(7): 1075-1079.